[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOHijT9nK40NkZX-FZRUm8A-LVXWbu8KNBJw5s1iK5yU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":84,"rows":91},"University of Zurich",[4],1033,false,123,42,623241,26,798,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Healthy",31,{"name":18,"count":19},"Pulmonary Hypertension",24,{"name":21,"count":22},"Stroke",17,{"name":24,"count":25},"High Altitude Pulmonary Hypertension",16,{"name":27,"count":25},"Chronic Obstructive Pulmonary Disease",{"name":29,"count":30},"Glaucoma",14,{"name":32,"count":33},"Spinal Cord Injury",11,{"name":35,"count":36},"Spinal Cord Injuries",10,[38,43,48,52,57,62,66,69,74,79],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05443178","Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy","2024-10-04","Nivaquine ®",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05598853","Intrathecal Double Checkpoint Inhibition","2025-12","intrathecal nivolumab and intrathecal ipilimumab",{"nctId":49,"briefTitle":50,"date":46,"intervention":51},"NCT06665568","Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients","Intranasal ketamine hydrochloride",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05105958","Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis","2025-12-01","Tideglusib",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06405464","Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","2025-12-31","VOCABRIA 30Mg",{"nctId":63,"briefTitle":64,"date":60,"intervention":65},"NCT06498531","HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men","Acetazolamide",{"nctId":67,"briefTitle":68,"date":60,"intervention":65},"NCT06498505","HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06399029","Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities","2026-04-22","Ruxolitinib Topical Cream",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT03899857","Pembrolizumab for Newly Diagnosed Glioblastoma","2026-04-30","Pembrolizumab",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05664464","Glutamate Inhibitors in Glioblastoma","2026-06","Gabapentin",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,318,359,427,462,483,510,528,546,564,589,617,640,663,681,702,801,823,844,868,893,920,938,956,974,992,1010,1041,1082,1113,1151,1188,1222,1260,1295,1322,1348,1370,1394,1417,1442,1465,1488,1514,1532,1557,1585,1610,1628,1653,1679,1704,1727,1751,1769,1787,1810,1831,1853,1876,1900,1918,1942,1960,1987,2013,2038,2056,2079,2102,2126,2144,2166,2201,2232,2262,2292,2310,2328,2346,2364,2389,2414,2437,2464,2482,2507,2525,2543,2567,2585,2611,2629,2653,2680,2705,2729,2753,2778,2802,2829,2847,2875,2899,2939,2972,3008,3032,3054,3076,3101,3119,3137,3161,3187,3210,3236,3260,3287,3305,3323,3347,3369,3391,3415,3437,3464,3482,3504,3527,3550,3573,3595,3620,3642,3665,3691,3715,3738,3762,3789,3807,3825,3843,3866,3889,3912,3935,3959,3983,4005,4030,4048,4066,4090,4112,4138,4162,4191,4209,4231,4254,4277,4300,4323,4346,4368,4391,4415,4437,4459,4477,4505,4523,4546,4569,4591,4609,4633,4657,4685,4711,4729,4755,4779,4813,4860,4896,4927,4957,4979,5001,5030,5064,5087,5114,5132,5156,5174,5197,5221,5246,5268,5286,5310,5336,5354,5376,5397,5418,5442,5460,5482,5506,5524,5542,5567,5585,5603,5628,5650,5673,5696,5719,5740,5764,5782,5806,5829,5852,5870,5895],{"intervention":93,"totalTrials":11,"cells":94},"ACETAZOLAMIDE oral",{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":114,"PHASE4":156,"NA":316},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT01427192","Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension","COMPLETED",[87],"2012-12","2010-11",23,[18,111],"Breathing-Related Sleep Disorder",[113],"acetazolamide",{"trials":115,"activeCount":97},[116,129,138,147],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":128},"NCT04915365","Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude","UNKNOWN",[88],"2022-12-31","2023-12-31","2021-05-01",100,[126,27,127],"Right Heart Function","Altitude Sickness",[65],{"nctId":130,"briefTitle":131,"status":119,"phases":132,"primaryCompletion":133,"completion":122,"start":134,"enrollment":124,"conditions":135,"interventions":137},"NCT04913389","Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD",[88],"2022-08-10","2021-06-01",[27,127,136],"Altitude Hypoxia",[65],{"nctId":139,"briefTitle":140,"status":105,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":19,"conditions":144,"interventions":146},"NCT02755298","Chronic Clinical Effect of Acetazolamide",[87,88],"2020-11","2016-10",[145],"Hypertension, Pulmonary",[65],{"nctId":148,"briefTitle":149,"status":105,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":155},"NCT02755259","Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension",[87,88],"2019-04-05","2017-01-01",33,[145],[65],{"trials":157,"activeCount":315,"soonestReadout":60},[158,167,175,182,188,194,201,208,216,224,231,241,246,253,261,270,277,283,291,300,308],{"nctId":159,"briefTitle":160,"status":105,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":166},"NCT03536507","Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude",[89],"2018-08-02","2018-05-15",185,[136],[93],{"nctId":168,"briefTitle":169,"status":105,"phases":170,"primaryCompletion":162,"completion":162,"start":171,"enrollment":172,"conditions":173,"interventions":174},"NCT03167034","Effect of Acetazolamide on Right Ventricular Function During Exercise in Patients With Respiratory Disease at Altitude",[89],"2017-05-24",110,[27],[93],{"nctId":176,"briefTitle":177,"status":119,"phases":178,"primaryCompletion":121,"completion":121,"start":179,"enrollment":124,"conditions":180,"interventions":181},"NCT03537924","Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude",[89],"2018-06-01",[136],[93],{"nctId":183,"briefTitle":184,"status":105,"phases":185,"primaryCompletion":162,"completion":162,"start":171,"enrollment":164,"conditions":186,"interventions":187},"NCT03177850","Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Respiratory Disease at Altitude",[89],[27],[93],{"nctId":189,"briefTitle":190,"status":105,"phases":191,"primaryCompletion":162,"completion":162,"start":171,"enrollment":172,"conditions":192,"interventions":193},"NCT03173508","Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With Respiratory Disease at Altitude",[89],[27],[93],{"nctId":195,"briefTitle":196,"status":105,"phases":197,"primaryCompletion":162,"completion":162,"start":163,"enrollment":198,"conditions":199,"interventions":200},"NCT03536429","Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude",[89],99,[136],[93],{"nctId":202,"briefTitle":203,"status":105,"phases":204,"primaryCompletion":162,"completion":162,"start":171,"enrollment":164,"conditions":205,"interventions":207},"NCT03156231","Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease",[89],[206],"Chronic Obstructive Pulmonary Disease (COPD)",[93],{"nctId":209,"briefTitle":210,"status":105,"phases":211,"primaryCompletion":212,"completion":212,"start":171,"enrollment":213,"conditions":214,"interventions":215},"NCT03165890","Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude",[89],"2017-07-24",78,[206],[93],{"nctId":63,"briefTitle":64,"status":217,"phases":218,"primaryCompletion":60,"completion":60,"start":219,"enrollment":220,"conditions":221,"interventions":223},"RECRUITING",[89],"2024-07-15",270,[222],"Sleep-Disordered Breathing",[65],{"nctId":225,"briefTitle":226,"status":105,"phases":227,"primaryCompletion":162,"completion":162,"start":163,"enrollment":228,"conditions":229,"interventions":230},"NCT03536520","Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude",[89],59,[136],[93],{"nctId":232,"briefTitle":233,"status":105,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT00714740","Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude",[89],"2008-12","2008-06",49,[239],"Obstructive Sleep Apnea Syndrome",[113],{"nctId":67,"briefTitle":68,"status":217,"phases":242,"primaryCompletion":60,"completion":60,"start":219,"enrollment":220,"conditions":243,"interventions":245},[89],[244],"High Altitude",[65],{"nctId":247,"briefTitle":248,"status":105,"phases":249,"primaryCompletion":162,"completion":162,"start":171,"enrollment":250,"conditions":251,"interventions":252},"NCT03177837","Effect of Acetazolamide on Exercise Performance in Patients With Respiratory Disease at Altitude",[89],176,[27],[93],{"nctId":254,"briefTitle":255,"status":105,"phases":256,"primaryCompletion":162,"completion":162,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT03540901","Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude",[89],"2018-05-22",112,[27],[93],{"nctId":262,"briefTitle":263,"status":105,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT00928655","Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude",[89],"2009-11","2009-06",51,[239],[113],{"nctId":271,"briefTitle":272,"status":105,"phases":273,"primaryCompletion":162,"completion":162,"start":171,"enrollment":274,"conditions":275,"interventions":276},"NCT03177811","Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude",[89],127,[27],[93],{"nctId":278,"briefTitle":279,"status":119,"phases":280,"primaryCompletion":121,"completion":121,"start":179,"enrollment":124,"conditions":281,"interventions":282},"NCT03539367","Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude",[89],[136],[93],{"nctId":284,"briefTitle":285,"status":119,"phases":286,"primaryCompletion":287,"completion":287,"start":179,"enrollment":288,"conditions":289,"interventions":290},"NCT03540914","Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.",[89],"2024-12-31",400,[136],[93],{"nctId":292,"briefTitle":293,"status":105,"phases":294,"primaryCompletion":295,"completion":295,"start":163,"enrollment":296,"conditions":297,"interventions":299},"NCT03561675","Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years",[89],"2019-08-31",349,[298],"Acute Mountain Sickness",[93],{"nctId":301,"briefTitle":302,"status":105,"phases":303,"primaryCompletion":304,"completion":304,"start":219,"enrollment":305,"conditions":306,"interventions":307},"NCT06499727","HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men",[89],"2025-08-31",303,[298],[65],{"nctId":309,"briefTitle":310,"status":105,"phases":311,"primaryCompletion":162,"completion":162,"start":163,"enrollment":312,"conditions":313,"interventions":314},"NCT03536455","Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude",[89],92,[136],[93],2,{"trials":317,"activeCount":97},[],{"intervention":319,"totalTrials":315,"cells":320},"Bryophyllum",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":342,"NA":357},{"trials":322,"activeCount":97},[],{"trials":324,"activeCount":97},[],{"trials":326,"activeCount":97},[],{"trials":328,"activeCount":97},[329],{"nctId":330,"briefTitle":331,"status":332,"phases":333,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":341},"NCT02129816","Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder","TERMINATED",[87,88],"2016-04-20","2017-07-09","2014-05",9,[339,340],"Overactive Bladder","Urge Urinary Incontinence",[319],{"trials":343,"activeCount":356,"soonestReadout":349},[344],{"nctId":345,"briefTitle":346,"status":347,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},"NCT06908044","Assessing the Therapeutic Potential of a Traditional Botanical Remedy for Menstrual Pain: Insights From a Prospective Observational Analysis","ACTIVE_NOT_RECRUITING",[89],"2028-06-30","2028-12-31","2025-01-01",25,[354],"Dysmenorrhea Primary",[319],1,{"trials":358,"activeCount":97},[],{"intervention":360,"totalTrials":361,"cells":362},"Oxygen",5,{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":385,"PHASE4":387,"NA":425},{"trials":364,"activeCount":97},[],{"trials":366,"activeCount":97},[],{"trials":368,"activeCount":356,"soonestReadout":373},[369],{"nctId":370,"briefTitle":371,"status":217,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":383},"NCT06636357","Nitrous Oxide in the Treatment of Acute Suicidal Ideation",[87],"2026-09-30","2025-01-13",85,[377,378,379,380,381,382],"Suicidality","EEG","Suicidal Ideation","Nitrous Oxide","Biomarkers \u002F Blood","Biomarkers \u002F Hair",[384,360],"50% N2O plus 50% O2",{"trials":386,"activeCount":97},[],{"trials":388,"activeCount":97},[389,400,410,418],{"nctId":390,"briefTitle":391,"status":119,"phases":392,"primaryCompletion":393,"completion":393,"start":336,"enrollment":394,"conditions":395,"interventions":398},"NCT02150616","Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep",[89],"2020-12",50,[396,397],"Precapillary Pulmonary Hypertension","Interstitial Lung Disease",[360,399],"Sham oxygen",{"nctId":401,"briefTitle":402,"status":105,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT02150590","Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Breathing and Sleep",[89],"2014-10-31","2014-06-01",32,[206],[360,409],"sham oxygen",{"nctId":411,"briefTitle":412,"status":105,"phases":413,"primaryCompletion":414,"completion":414,"start":336,"enrollment":415,"conditions":416,"interventions":417},"NCT02143687","Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance",[89],"2021-10",30,[396,397],[360,399],{"nctId":419,"briefTitle":420,"status":105,"phases":421,"primaryCompletion":404,"completion":404,"start":336,"enrollment":406,"conditions":422,"interventions":423},"NCT02143609","Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance",[89],[206],[424,409],"oxygen",{"trials":426,"activeCount":97},[],{"intervention":428,"totalTrials":315,"cells":429},"Temozolomide",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":431,"activeCount":97},[],{"trials":433,"activeCount":97},[],{"trials":435,"activeCount":356,"soonestReadout":82},[436,447],{"nctId":437,"briefTitle":438,"status":119,"phases":439,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},"NCT00521482","Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma",[87],"2009-01","2007-09",40,[444],"Glioblastoma",[428,446],"Temozolomide plus Thalidomide",{"nctId":80,"briefTitle":81,"status":217,"phases":448,"primaryCompletion":82,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},[86,87],"2026-12","2023-01-01",120,[444],[83,454,455,428],"Sulfasalazine","Memantine",{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":97},[],{"intervention":78,"totalTrials":356,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":465,"activeCount":97},[],{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":356,"soonestReadout":77},[470],{"nctId":75,"briefTitle":76,"status":347,"phases":471,"primaryCompletion":77,"completion":449,"start":472,"enrollment":473,"conditions":474,"interventions":476},[87],"2020-10-21",56,[475],"Newly Diagnosed Glioblastoma",[78],{"trials":478,"activeCount":97},[],{"trials":480,"activeCount":97},[],{"trials":482,"activeCount":97},[],{"intervention":484,"totalTrials":356,"cells":485},"ALUTARD SQ® Felis domesticus",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":487,"activeCount":97},[],{"trials":489,"activeCount":97},[],{"trials":491,"activeCount":356,"soonestReadout":496},[492],{"nctId":493,"briefTitle":494,"status":217,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":503},"NCT06960382","Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma",[86,87],"2027-05-31","2028-03-31","2025-08-20",36,[501,502],"Allergic Rhinitis","Allergic Asthma",[484],{"trials":505,"activeCount":97},[],{"trials":507,"activeCount":97},[],{"trials":509,"activeCount":97},[],{"intervention":83,"totalTrials":356,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":513,"activeCount":97},[],{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":356,"soonestReadout":82},[518],{"nctId":80,"briefTitle":81,"status":217,"phases":519,"primaryCompletion":82,"completion":449,"start":450,"enrollment":451,"conditions":520,"interventions":521},[86,87],[444],[83,454,455,428],{"trials":523,"activeCount":97},[],{"trials":525,"activeCount":97},[],{"trials":527,"activeCount":97},[],{"intervention":454,"totalTrials":356,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":531,"activeCount":97},[],{"trials":533,"activeCount":97},[],{"trials":535,"activeCount":356,"soonestReadout":82},[536],{"nctId":80,"briefTitle":81,"status":217,"phases":537,"primaryCompletion":82,"completion":449,"start":450,"enrollment":451,"conditions":538,"interventions":539},[86,87],[444],[83,454,455,428],{"trials":541,"activeCount":97},[],{"trials":543,"activeCount":97},[],{"trials":545,"activeCount":97},[],{"intervention":455,"totalTrials":356,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":97},[],{"trials":553,"activeCount":356,"soonestReadout":82},[554],{"nctId":80,"briefTitle":81,"status":217,"phases":555,"primaryCompletion":82,"completion":449,"start":450,"enrollment":451,"conditions":556,"interventions":557},[86,87],[444],[83,454,455,428],{"trials":559,"activeCount":97},[],{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[],{"intervention":565,"totalTrials":356,"cells":566},"Propranolol",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":356,"soonestReadout":350},[573],{"nctId":574,"briefTitle":575,"status":217,"phases":576,"primaryCompletion":350,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT03083431","Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity",[87],"2029-12-31","2022-09-22",276,[581],"Retinopathy of Prematurity",[565],{"trials":584,"activeCount":97},[],{"trials":586,"activeCount":97},[],{"trials":588,"activeCount":97},[],{"intervention":590,"totalTrials":356,"cells":591},"Control Group",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":593,"activeCount":97},[],{"trials":595,"activeCount":97},[],{"trials":597,"activeCount":356,"soonestReadout":603},[598],{"nctId":599,"briefTitle":600,"status":601,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":609},"NCT03643367","Sevoflurane Sedation in Patients With Septic Shock","NOT_YET_RECRUITING",[87],"2027-02","2027-11","2026-01",153,[608],"Shock, Septic",[610,590],"Sevoflurane",{"trials":612,"activeCount":97},[],{"trials":614,"activeCount":97},[],{"trials":616,"activeCount":97},[],{"intervention":73,"totalTrials":356,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":620,"activeCount":97},[],{"trials":622,"activeCount":97},[],{"trials":624,"activeCount":356,"soonestReadout":72},[625],{"nctId":70,"briefTitle":71,"status":347,"phases":626,"primaryCompletion":72,"completion":627,"start":628,"enrollment":629,"conditions":630,"interventions":633},[87],"2026-05","2024-10-10",22,[631,632],"Exanthema","Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy",[73],{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"intervention":641,"totalTrials":356,"cells":642},"Vortioxetine",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":644,"activeCount":97},[],{"trials":646,"activeCount":97},[],{"trials":648,"activeCount":356,"soonestReadout":653},[649],{"nctId":650,"briefTitle":651,"status":601,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":213,"conditions":655,"interventions":656},"NCT07284628","Vortioxetine for Newly Diagnosed Glioblastoma",[87],"2029-06","2025-12-15",[444],[641],{"trials":658,"activeCount":97},[],{"trials":660,"activeCount":97},[],{"trials":662,"activeCount":97},[],{"intervention":384,"totalTrials":356,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":97},[],{"trials":668,"activeCount":97},[],{"trials":670,"activeCount":356,"soonestReadout":373},[671],{"nctId":370,"briefTitle":371,"status":217,"phases":672,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":673,"interventions":674},[87],[377,378,379,380,381,382],[384,360],{"trials":676,"activeCount":97},[],{"trials":678,"activeCount":97},[],{"trials":680,"activeCount":97},[],{"intervention":56,"totalTrials":356,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":684,"activeCount":97},[],{"trials":686,"activeCount":97},[],{"trials":688,"activeCount":356,"soonestReadout":55},[689],{"nctId":53,"briefTitle":54,"status":601,"phases":690,"primaryCompletion":55,"completion":691,"start":55,"enrollment":692,"conditions":693,"interventions":695},[87],"2026-03-01",98,[694],"Amyotrophic Lateral Sclerosis",[56],{"trials":697,"activeCount":97},[],{"trials":699,"activeCount":97},[],{"trials":701,"activeCount":97},[],{"intervention":610,"totalTrials":337,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":726,"PHASE4":741,"NA":761},{"trials":705,"activeCount":97},[],{"trials":707,"activeCount":97},[],{"trials":709,"activeCount":356,"soonestReadout":603},[710,714],{"nctId":599,"briefTitle":600,"status":601,"phases":711,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":712,"interventions":713},[87],[608],[610,590],{"nctId":715,"briefTitle":716,"status":717,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":97,"conditions":721,"interventions":723},"NCT02946437","Sevoflurane in Subarachnoidal Haemorrhage","WITHDRAWN",[87],"2019-12-31","2015-11-01",[722],"Subarachnoid Haemorrhage (SAH)",[610,724,725],"Propofol","Midazolam",{"trials":727,"activeCount":97},[728],{"nctId":729,"briefTitle":730,"status":105,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":739},"NCT04355962","Sevoflurane in COVID-19 ARDS (SevCov)",[88],"2021-06-25","2021-07-16","2020-04-23",68,[737,738],"ARDS, Human","Coronavirus",[610,740],"Intravenous drug",{"trials":742,"activeCount":97},[743,751],{"nctId":744,"briefTitle":745,"status":119,"phases":746,"primaryCompletion":235,"completion":235,"start":747,"enrollment":36,"conditions":748,"interventions":750},"NCT00526695","Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion",[89],"2005-01",[749],"Ischemia\u002FReperfusion Injury",[610],{"nctId":752,"briefTitle":753,"status":105,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT02005770","Anesthesia and Circulating Tumor Cells in Breast Cancer",[89],"2018-04","2014-03",221,[759],"Female Breast Carcinoma",[610,724],{"trials":762,"activeCount":97},[763,772,781,792],{"nctId":764,"briefTitle":765,"status":105,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"conditions":769,"interventions":771},"NCT00516711","Role of Volatile Anesthetics for Hepatic Protection",[90],"2007-12","2006-03",[770],"Reperfusion Injury",[610],{"nctId":773,"briefTitle":774,"status":105,"phases":775,"primaryCompletion":265,"completion":776,"start":777,"enrollment":451,"conditions":778,"interventions":780},"NCT00924222","Organ Protection With Sevoflurane Postconditioning After Cardiac Surgery With Cardiopulmonary Bypass",[90],"2009-12","2007-10",[779],"Cardiac On-pump Surgery",[610,724],{"nctId":782,"briefTitle":783,"status":105,"phases":784,"primaryCompletion":785,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT00518908","Organ Protection With Sevoflurane Postconditioning",[90],"2010-08","2010-09","2008-01",125,[790],"Hepatectomy",[610],{"nctId":793,"briefTitle":794,"status":105,"phases":795,"primaryCompletion":796,"completion":797,"start":440,"enrollment":692,"conditions":798,"interventions":800},"NCT00913276","Conditioning With Volatile Anesthetics in Liver Transplantation",[90],"2012-08","2012-10",[799],"End-stage Liver Disease",[724,610],{"intervention":47,"totalTrials":356,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":804,"activeCount":97},[],{"trials":806,"activeCount":356,"soonestReadout":46},[807],{"nctId":44,"briefTitle":45,"status":347,"phases":808,"primaryCompletion":46,"completion":46,"start":809,"enrollment":11,"conditions":810,"interventions":814},[86],"2022-11-25",[811,812,813],"Leptomeningeal Metastasis","Non-small Cell Lung Cancer Stage IV","Melanoma Stage IV",[47],{"trials":816,"activeCount":97},[],{"trials":818,"activeCount":97},[],{"trials":820,"activeCount":97},[],{"trials":822,"activeCount":97},[],{"intervention":42,"totalTrials":356,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":826,"activeCount":97},[],{"trials":828,"activeCount":356,"soonestReadout":41},[829],{"nctId":39,"briefTitle":40,"status":217,"phases":830,"primaryCompletion":41,"completion":831,"start":832,"enrollment":25,"conditions":833,"interventions":835},[86],"2025-06-01","2022-01-04",[834],"Tuberculosis Infection",[42],{"trials":837,"activeCount":97},[],{"trials":839,"activeCount":97},[],{"trials":841,"activeCount":97},[],{"trials":843,"activeCount":97},[],{"intervention":51,"totalTrials":356,"cells":845},{"EARLY_PHASE1":846,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":847,"activeCount":356,"soonestReadout":46},[848],{"nctId":49,"briefTitle":50,"status":601,"phases":849,"primaryCompletion":46,"completion":449,"start":850,"enrollment":124,"conditions":851,"interventions":857},[85],"2025-04",[852,853,854,855,856],"Depressive Symptoms Mild to Moderate in Severity","Anxiety","Quality of Life (QOL)","Caregiver Burden","Sleep Quality",[51],{"trials":859,"activeCount":97},[],{"trials":861,"activeCount":97},[],{"trials":863,"activeCount":97},[],{"trials":865,"activeCount":97},[],{"trials":867,"activeCount":97},[],{"intervention":869,"totalTrials":356,"cells":870},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":872,"activeCount":97},[],{"trials":874,"activeCount":97},[],{"trials":876,"activeCount":97},[],{"trials":878,"activeCount":97},[],{"trials":880,"activeCount":97},[],{"trials":882,"activeCount":356,"soonestReadout":887},[883],{"nctId":884,"briefTitle":885,"status":601,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":415,"conditions":889,"interventions":892},"NCT07421947","Effects of Fecal Microbiota Transplantation in Patients With Type 2 Diabetes and Coronary Artery Disease (CAD-Microbiome) - A Pilot Study",[90],"2028-12","2026-04",[890,891],"Coronary Artery Disease","Type 2 Diabetes Mellitus (T2DM)",[869],{"intervention":61,"totalTrials":356,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":896,"activeCount":97},[],{"trials":898,"activeCount":97},[],{"trials":900,"activeCount":97},[],{"trials":902,"activeCount":97},[],{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":356,"soonestReadout":60},[907],{"nctId":58,"briefTitle":59,"status":217,"phases":908,"primaryCompletion":60,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":914},[],"2026-06-30","2022-03-01",600,[913],"HIV Infections",[61,915,916,917,918,919],"EDURANT 25Mg","Cabotegravir Injectable Suspension","Rilpivirine Injectable Suspension","Intact proviral DNA assay","Full-length sequencing",{"intervention":915,"totalTrials":356,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":923,"activeCount":97},[],{"trials":925,"activeCount":97},[],{"trials":927,"activeCount":97},[],{"trials":929,"activeCount":97},[],{"trials":931,"activeCount":97},[],{"trials":933,"activeCount":356,"soonestReadout":60},[934],{"nctId":58,"briefTitle":59,"status":217,"phases":935,"primaryCompletion":60,"completion":909,"start":910,"enrollment":911,"conditions":936,"interventions":937},[],[913],[61,915,916,917,918,919],{"intervention":916,"totalTrials":356,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":941,"activeCount":97},[],{"trials":943,"activeCount":97},[],{"trials":945,"activeCount":97},[],{"trials":947,"activeCount":97},[],{"trials":949,"activeCount":97},[],{"trials":951,"activeCount":356,"soonestReadout":60},[952],{"nctId":58,"briefTitle":59,"status":217,"phases":953,"primaryCompletion":60,"completion":909,"start":910,"enrollment":911,"conditions":954,"interventions":955},[],[913],[61,915,916,917,918,919],{"intervention":917,"totalTrials":356,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":959,"activeCount":97},[],{"trials":961,"activeCount":97},[],{"trials":963,"activeCount":97},[],{"trials":965,"activeCount":97},[],{"trials":967,"activeCount":97},[],{"trials":969,"activeCount":356,"soonestReadout":60},[970],{"nctId":58,"briefTitle":59,"status":217,"phases":971,"primaryCompletion":60,"completion":909,"start":910,"enrollment":911,"conditions":972,"interventions":973},[],[913],[61,915,916,917,918,919],{"intervention":918,"totalTrials":356,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":977,"activeCount":97},[],{"trials":979,"activeCount":97},[],{"trials":981,"activeCount":97},[],{"trials":983,"activeCount":97},[],{"trials":985,"activeCount":97},[],{"trials":987,"activeCount":356,"soonestReadout":60},[988],{"nctId":58,"briefTitle":59,"status":217,"phases":989,"primaryCompletion":60,"completion":909,"start":910,"enrollment":911,"conditions":990,"interventions":991},[],[913],[61,915,916,917,918,919],{"intervention":919,"totalTrials":356,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":995,"activeCount":97},[],{"trials":997,"activeCount":97},[],{"trials":999,"activeCount":97},[],{"trials":1001,"activeCount":97},[],{"trials":1003,"activeCount":97},[],{"trials":1005,"activeCount":356,"soonestReadout":60},[1006],{"nctId":58,"briefTitle":59,"status":217,"phases":1007,"primaryCompletion":60,"completion":909,"start":910,"enrollment":911,"conditions":1008,"interventions":1009},[],[913],[61,915,916,917,918,919],{"intervention":399,"totalTrials":1011,"cells":1012},4,{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1039},{"trials":1014,"activeCount":97},[],{"trials":1016,"activeCount":97},[],{"trials":1018,"activeCount":97},[],{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":97},[1023,1027,1031,1035],{"nctId":390,"briefTitle":391,"status":119,"phases":1024,"primaryCompletion":393,"completion":393,"start":336,"enrollment":394,"conditions":1025,"interventions":1026},[89],[396,397],[360,399],{"nctId":401,"briefTitle":402,"status":105,"phases":1028,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":1029,"interventions":1030},[89],[206],[360,409],{"nctId":411,"briefTitle":412,"status":105,"phases":1032,"primaryCompletion":414,"completion":414,"start":336,"enrollment":415,"conditions":1033,"interventions":1034},[89],[396,397],[360,399],{"nctId":419,"briefTitle":420,"status":105,"phases":1036,"primaryCompletion":404,"completion":404,"start":336,"enrollment":406,"conditions":1037,"interventions":1038},[89],[206],[424,409],{"trials":1040,"activeCount":97},[],{"intervention":1042,"totalTrials":1043,"cells":1044},"Daptomycin",3,{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1068,"PHASE4":1070,"NA":1080},{"trials":1046,"activeCount":97},[],{"trials":1048,"activeCount":97},[],{"trials":1050,"activeCount":97},[1051,1060],{"nctId":1052,"briefTitle":1053,"status":119,"phases":1054,"primaryCompletion":1055,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT01171547","Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration",[87],"2010-02",15,[1058],"Bacteremia",[1042],{"nctId":1061,"briefTitle":1062,"status":119,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":776,"enrollment":1056,"conditions":1065,"interventions":1067},"NCT01212432","Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study",[87],"2010-03",[1066],"Gram-Positive Bacterial Infections",[1042],{"trials":1069,"activeCount":97},[],{"trials":1071,"activeCount":97},[1072],{"nctId":1073,"briefTitle":1074,"status":717,"phases":1075,"primaryCompletion":143,"completion":143,"start":1076,"enrollment":97,"conditions":1077,"interventions":1079},"NCT02241941","Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury",[89],"2014-09",[1078],"Burn Injury",[1042],{"trials":1081,"activeCount":97},[],{"intervention":1083,"totalTrials":315,"cells":1084},"Dexamethasone",{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1111},{"trials":1086,"activeCount":97},[],{"trials":1088,"activeCount":97},[],{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[1095,1104],{"nctId":1096,"briefTitle":1097,"status":105,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT02450968","Altitude Related Illness In Patients With Respiratory Disease",[89],"2015-12","2015-05",124,[206],[1083],{"nctId":1105,"briefTitle":1106,"status":105,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1100,"enrollment":1101,"conditions":1109,"interventions":1110},"NCT02450994","Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude",[89],"2015-09",[206],[1083],{"trials":1112,"activeCount":97},[],{"intervention":1114,"totalTrials":315,"cells":1115},"Paracetamol",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1149},{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":97},[],{"trials":1123,"activeCount":97},[],{"trials":1125,"activeCount":97},[1126,1137],{"nctId":1127,"briefTitle":1128,"status":105,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1136},"NCT00534651","Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease",[89],"2010-01","2006-11",37,[1134,1135],"Coronary Arteriosclerosis","Endothelial Function",[1114],{"nctId":1138,"briefTitle":1139,"status":119,"phases":1140,"primaryCompletion":1141,"completion":60,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1146},"NCT03781544","Effects of Opioids and NSAIDs on Sympathetic Nervous System and Vascular Function",[89],"2025-07-31","2019-01-01",90,[1145,15],"Osteoarthritis of Multiple Joints of Ankle or Foot",[1147,1114,1148],"Tramadol","Diclofenac",{"trials":1150,"activeCount":97},[],{"intervention":1152,"totalTrials":315,"cells":1153},"Desflurane",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1186},{"trials":1155,"activeCount":97},[],{"trials":1157,"activeCount":97},[],{"trials":1159,"activeCount":97},[],{"trials":1161,"activeCount":97},[],{"trials":1163,"activeCount":97},[1164,1174],{"nctId":1165,"briefTitle":1166,"status":105,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1173},"NCT01452256","Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery",[89],"2014-12","2011-12",460,[1172],"Thoracic Surgery",[1152,724],{"nctId":1175,"briefTitle":1176,"status":105,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":143,"enrollment":1180,"conditions":1181,"interventions":1185},"NCT02335151","CTC Pancreatic Adenocarcinoma",[89],"2019-09","2019-10",86,[1182,1183,1184],"Adenocarcinoma","Circulating Tumor Cells","Pancreatic Neoplasms",[1152],{"trials":1187,"activeCount":97},[],{"intervention":1189,"totalTrials":315,"cells":1190},"ferric carboxymaltose",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1220},{"trials":1192,"activeCount":97},[],{"trials":1194,"activeCount":97},[],{"trials":1196,"activeCount":97},[],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[1201,1211],{"nctId":1202,"briefTitle":1203,"status":332,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1210},"NCT01978028","Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose",[89],"2017-12-31","2013-10",20,[1209],"Heart Failure",[1189],{"nctId":1212,"briefTitle":1213,"status":105,"phases":1214,"primaryCompletion":107,"completion":107,"start":1215,"enrollment":1056,"conditions":1216,"interventions":1219},"NCT01245777","Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy",[89],"2009-10",[1217,1218],"Restless Leg Syndrome","Iron Deficiency Anemia",[1189],{"trials":1221,"activeCount":97},[],{"intervention":1223,"totalTrials":315,"cells":1224},"fluid resuscitation",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1246,"NA":1258},{"trials":1226,"activeCount":97},[],{"trials":1228,"activeCount":97},[],{"trials":1230,"activeCount":97},[],{"trials":1232,"activeCount":97},[1233],{"nctId":1234,"briefTitle":1235,"status":105,"phases":1236,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1244},"NCT01120730","Fluid Resuscitation With HES 200\u002F0.5 10% in Severe Burn Injury",[88],"1998-09","2009-03","1997-04",28,[1242,1243],"Survival","Renal Failure",[1223,1245],"Fluid resuscitation",{"trials":1247,"activeCount":97},[1248],{"nctId":1249,"briefTitle":1250,"status":119,"phases":1251,"primaryCompletion":1252,"completion":1252,"start":265,"enrollment":1253,"conditions":1254,"interventions":1256},"NCT01012648","Early Fluid Resuscitation With Balanced HES 130\u002F0.4 [6%] in Severe Burn Injury",[89],"2013-01",48,[1255],"Burns",[1245,1257],"HES 130\u002F0.4 (6%), Voluven balanced vs. Lactated Ringer's solution",{"trials":1259,"activeCount":97},[],{"intervention":1261,"totalTrials":315,"cells":1262},"recombinant human Erythropoietin",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1280,"NA":1293},{"trials":1264,"activeCount":97},[],{"trials":1266,"activeCount":97},[],{"trials":1268,"activeCount":97},[],{"trials":1270,"activeCount":97},[1271],{"nctId":1272,"briefTitle":1273,"status":119,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":756,"enrollment":451,"conditions":1277,"interventions":1279},"NCT02076373","Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants",[88],"2023-12","2024-03",[1278],"Intraventricular Hemorrhage of Prematurity",[1261],{"trials":1281,"activeCount":97},[1282],{"nctId":1283,"briefTitle":1284,"status":105,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":394,"conditions":1288,"interventions":1290},"NCT03317210","Intravenous Treatment of Anemia in Pregnancy",[89],"2006-07-31","2002-09-01",[1289],"Anemia",[1291,1292],"iron sucrose","recombinant human erythropoietin",{"trials":1294,"activeCount":97},[],{"intervention":1296,"totalTrials":356,"cells":1297},"Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1320},{"trials":1299,"activeCount":97},[],{"trials":1301,"activeCount":97},[],{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"trials":1307,"activeCount":97},[1308],{"nctId":1309,"briefTitle":1310,"status":119,"phases":1311,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1319},"NCT02487719","Different Iron Supplements for Prevention of Anemia in Pregnancy",[89],"2016-06","2016-08","2015-06",150,[1317,1318],"Iron-Deficiency Anemia","Pregnancy",[1296],{"trials":1321,"activeCount":97},[],{"intervention":1323,"totalTrials":356,"cells":1324},"Vaccination against TBEV",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1346},{"trials":1326,"activeCount":97},[],{"trials":1328,"activeCount":97},[],{"trials":1330,"activeCount":97},[],{"trials":1332,"activeCount":97},[],{"trials":1334,"activeCount":97},[1335],{"nctId":1336,"briefTitle":1337,"status":105,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1345},"NCT00461695","Influence of Persistent CMV-infection on Immune Senescence",[89],"2008-08","2010-12","2007-05",183,[1344],"Immune Senescence",[1323],{"trials":1347,"activeCount":97},[],{"intervention":1349,"totalTrials":356,"cells":1350},"pentoxyfilline",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1368},{"trials":1352,"activeCount":97},[],{"trials":1354,"activeCount":97},[],{"trials":1356,"activeCount":97},[],{"trials":1358,"activeCount":97},[],{"trials":1360,"activeCount":97},[1361],{"nctId":1362,"briefTitle":1363,"status":105,"phases":1364,"primaryCompletion":1130,"completion":1130,"start":768,"enrollment":124,"conditions":1365,"interventions":1367},"NCT00957619","Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)",[89],[1366],"Liver Regeneration",[1349],{"trials":1369,"activeCount":97},[],{"intervention":1371,"totalTrials":356,"cells":1372},"Vancomycin",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1392},{"trials":1374,"activeCount":97},[],{"trials":1376,"activeCount":97},[],{"trials":1378,"activeCount":97},[],{"trials":1380,"activeCount":97},[],{"trials":1382,"activeCount":97},[1383],{"nctId":1384,"briefTitle":1385,"status":119,"phases":1386,"primaryCompletion":1387,"completion":287,"start":134,"enrollment":124,"conditions":1388,"interventions":1391},"NCT04856878","Effect of Vancomycin After Catheter Replacement",[89],"2024-06-30",[1389,1390],"Central Line-associated Bloodstream Infection (CLABSI)","Catheter-related Bloodstream Infection",[1371],{"trials":1393,"activeCount":97},[],{"intervention":1395,"totalTrials":356,"cells":1396},"Steroid active treatment",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1403,"PHASE4":1405,"NA":1415},{"trials":1398,"activeCount":97},[],{"trials":1400,"activeCount":97},[],{"trials":1402,"activeCount":97},[],{"trials":1404,"activeCount":97},[],{"trials":1406,"activeCount":97},[1407],{"nctId":1408,"briefTitle":1409,"status":717,"phases":1410,"primaryCompletion":1313,"completion":1313,"start":1411,"enrollment":97,"conditions":1412,"interventions":1414},"NCT01429870","Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis",[89],"2011-08",[1413],"Psoriasis",[1395],{"trials":1416,"activeCount":97},[],{"intervention":1418,"totalTrials":356,"cells":1419},"acute infusion of nitroglycerine into the pulmonary artery",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1440},{"trials":1421,"activeCount":97},[],{"trials":1423,"activeCount":97},[],{"trials":1425,"activeCount":97},[],{"trials":1427,"activeCount":97},[],{"trials":1429,"activeCount":97},[1430],{"nctId":1431,"briefTitle":1432,"status":105,"phases":1433,"completion":1434,"start":1435,"enrollment":1207,"conditions":1436,"interventions":1439},"NCT00449059","Nitrate and Hypertension in Heart Transplanted Patients",[89],"2004-12","2003-01",[1437,1438],"Hypertension","Heart Transplantation",[1418],{"trials":1441,"activeCount":97},[],{"intervention":1443,"totalTrials":356,"cells":1444},"intravenous iron carboxymaltose",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1463},{"trials":1446,"activeCount":97},[],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"trials":1452,"activeCount":97},[],{"trials":1454,"activeCount":97},[1455],{"nctId":1456,"briefTitle":1457,"status":105,"phases":1458,"primaryCompletion":1076,"completion":1168,"start":1459,"enrollment":19,"conditions":1460,"interventions":1462},"NCT01374776","Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women",[89],"2013-02",[1461],"Non Anemic Patients With Iron Deficiency (Low Ferritin Value)",[1443],{"trials":1464,"activeCount":97},[],{"intervention":1466,"totalTrials":356,"cells":1467},"Ferinject ®",{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1486},{"trials":1469,"activeCount":97},[],{"trials":1471,"activeCount":97},[],{"trials":1473,"activeCount":97},[],{"trials":1475,"activeCount":97},[],{"trials":1477,"activeCount":97},[1478],{"nctId":1479,"briefTitle":1480,"status":332,"phases":1481,"primaryCompletion":107,"completion":107,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1485},"NCT00706667","Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery",[89],"2008-05",75,[1218],[1466],{"trials":1487,"activeCount":97},[],{"intervention":1489,"totalTrials":356,"cells":1490},"Oxytocin",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1512},{"trials":1492,"activeCount":97},[],{"trials":1494,"activeCount":97},[],{"trials":1496,"activeCount":97},[],{"trials":1498,"activeCount":97},[],{"trials":1500,"activeCount":97},[1501],{"nctId":1502,"briefTitle":1503,"status":105,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":1507,"conditions":1508,"interventions":1510},"NCT03651882","Oxytocin i.m.\u002Fi.v. Versus Carbetocin i.v. in Elective Cesarean Sections",[89],"2022-01-10","2018-08-07",550,[1509],"Postpartum Hemorrhage",[1489,1511],"Carbetocin",{"trials":1513,"activeCount":97},[],{"intervention":1511,"totalTrials":356,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1530},{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"trials":1523,"activeCount":97},[],{"trials":1525,"activeCount":97},[1526],{"nctId":1502,"briefTitle":1503,"status":105,"phases":1527,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":1507,"conditions":1528,"interventions":1529},[89],[1509],[1489,1511],{"trials":1531,"activeCount":97},[],{"intervention":1533,"totalTrials":356,"cells":1534},"Colistin",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1543,"NA":1555},{"trials":1536,"activeCount":97},[],{"trials":1538,"activeCount":97},[],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[1545],{"nctId":1546,"briefTitle":1547,"status":119,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":36,"conditions":1552,"interventions":1554},"NCT02081560","Colistin Pharmacokinetics in Continuous Renal Replacement Therapy",[89],"2015-07","2015-08","2013-11",[1553],"Infection",[1533],{"trials":1556,"activeCount":97},[],{"intervention":1558,"totalTrials":356,"cells":1559},"Nephrotrans",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1568,"NA":1583},{"trials":1561,"activeCount":97},[],{"trials":1563,"activeCount":97},[],{"trials":1565,"activeCount":97},[],{"trials":1567,"activeCount":97},[],{"trials":1569,"activeCount":97},[1570],{"nctId":1571,"briefTitle":1572,"status":105,"phases":1573,"primaryCompletion":1574,"completion":1575,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1582},"NCT03102996","Preserve-Transplant Study",[89],"2021-06-29","2021-07-26","2017-06-12",240,[1579,1580,1581],"Acidosis","Renal Insufficiency","Kidney Transplantation",[1558],{"trials":1584,"activeCount":97},[],{"intervention":1586,"totalTrials":356,"cells":1587},"Valsartan\u002FSacubitril or placebo",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1594,"PHASE4":1596,"NA":1608},{"trials":1589,"activeCount":97},[],{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[],{"trials":1595,"activeCount":97},[],{"trials":1597,"activeCount":97},[1598],{"nctId":1599,"briefTitle":1600,"status":105,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1606},"NCT03168568","Differential Vascular and Endocrine Effects of Valsartan\u002FSacubitril in Heart Failure With Reduced Ejection Fraction",[89],"2020-09-05","2017-05-04",79,[1209],[1586,1607],"Valsartan or placebo",{"trials":1609,"activeCount":97},[],{"intervention":1607,"totalTrials":356,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1626},{"trials":1613,"activeCount":97},[],{"trials":1615,"activeCount":97},[],{"trials":1617,"activeCount":97},[],{"trials":1619,"activeCount":97},[],{"trials":1621,"activeCount":97},[1622],{"nctId":1599,"briefTitle":1600,"status":105,"phases":1623,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1624,"interventions":1625},[89],[1209],[1586,1607],{"trials":1627,"activeCount":97},[],{"intervention":1629,"totalTrials":356,"cells":1630},"Dipeptiven",{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1651},{"trials":1632,"activeCount":97},[],{"trials":1634,"activeCount":97},[],{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[],{"trials":1640,"activeCount":97},[1641],{"nctId":1642,"briefTitle":1643,"status":105,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":747,"enrollment":1646,"conditions":1647,"interventions":1650},"NCT02130674","Optimized Therapy in Severe Traumatic Brain Injured Patients",[89],"2011-02",12,[1648,1649],"Traumatic Brain Injury","Coma",[1629],{"trials":1652,"activeCount":97},[],{"intervention":1654,"totalTrials":356,"cells":1655},"Erythropoietin\u002FFerric carboxymaltose\u002FVitamin B12\u002FFolic Acid",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1662,"PHASE4":1664,"NA":1677},{"trials":1657,"activeCount":97},[],{"trials":1659,"activeCount":97},[],{"trials":1661,"activeCount":97},[],{"trials":1663,"activeCount":97},[],{"trials":1665,"activeCount":97},[1666],{"nctId":1667,"briefTitle":1668,"status":105,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},"NCT02031289","Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.",[89],"2017-12","2018-05","2013-12",1003,[1289,1675],"Iron Deficiency",[1654],{"trials":1678,"activeCount":97},[],{"intervention":1680,"totalTrials":356,"cells":1681},"ropivacaine",{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1690,"NA":1702},{"trials":1683,"activeCount":97},[],{"trials":1685,"activeCount":97},[],{"trials":1687,"activeCount":97},[],{"trials":1689,"activeCount":97},[],{"trials":1691,"activeCount":97},[1692],{"nctId":1693,"briefTitle":1694,"status":105,"phases":1695,"primaryCompletion":1696,"completion":1697,"start":1130,"enrollment":1698,"conditions":1699,"interventions":1701},"NCT00900913","Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral Nerve Excitability",[89],"2011-05","2011-07",34,[1700],"Healthy Volunteers",[1680],{"trials":1703,"activeCount":97},[],{"intervention":1705,"totalTrials":356,"cells":1706},"Rasagiline",{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1715,"NA":1725},{"trials":1708,"activeCount":97},[],{"trials":1710,"activeCount":97},[],{"trials":1712,"activeCount":97},[],{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[1717],{"nctId":1718,"briefTitle":1719,"status":332,"phases":1720,"primaryCompletion":797,"completion":797,"start":1721,"enrollment":356,"conditions":1722,"interventions":1724},"NCT01178047","Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease",[89],"2011-09",[1723],"Parkinson's Disease",[1705],{"trials":1726,"activeCount":97},[],{"intervention":1728,"totalTrials":356,"cells":1729},"xylometazoline",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1749},{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"trials":1735,"activeCount":97},[],{"trials":1737,"activeCount":97},[],{"trials":1739,"activeCount":97},[1740],{"nctId":1741,"briefTitle":1742,"status":105,"phases":1743,"primaryCompletion":1744,"completion":1744,"start":1745,"enrollment":1646,"conditions":1746,"interventions":1748},"NCT00630474","Nasal Decongestion and Obstructive Sleep Apnea",[89],"2005-04","2004-01",[239,1747],"Rhinitis",[1728],{"trials":1750,"activeCount":97},[],{"intervention":1147,"totalTrials":356,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1759,"PHASE4":1761,"NA":1767},{"trials":1754,"activeCount":97},[],{"trials":1756,"activeCount":97},[],{"trials":1758,"activeCount":97},[],{"trials":1760,"activeCount":97},[],{"trials":1762,"activeCount":97},[1763],{"nctId":1138,"briefTitle":1139,"status":119,"phases":1764,"primaryCompletion":1141,"completion":60,"start":1142,"enrollment":1143,"conditions":1765,"interventions":1766},[89],[1145,15],[1147,1114,1148],{"trials":1768,"activeCount":97},[],{"intervention":1148,"totalTrials":356,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1785},{"trials":1772,"activeCount":97},[],{"trials":1774,"activeCount":97},[],{"trials":1776,"activeCount":97},[],{"trials":1778,"activeCount":97},[],{"trials":1780,"activeCount":97},[1781],{"nctId":1138,"briefTitle":1139,"status":119,"phases":1782,"primaryCompletion":1141,"completion":60,"start":1142,"enrollment":1143,"conditions":1783,"interventions":1784},[89],[1145,15],[1147,1114,1148],{"trials":1786,"activeCount":97},[],{"intervention":1788,"totalTrials":356,"cells":1789},"Esomeprazole",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1798,"NA":1808},{"trials":1791,"activeCount":97},[],{"trials":1793,"activeCount":97},[],{"trials":1795,"activeCount":97},[],{"trials":1797,"activeCount":97},[],{"trials":1799,"activeCount":97},[1800],{"nctId":1801,"briefTitle":1802,"status":105,"phases":1803,"completion":777,"start":1804,"conditions":1805,"interventions":1807},"NCT00574925","Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients",[89],"2003-11",[1806],"Gastroesophageal Reflux Disease (GERD)",[1788],{"trials":1809,"activeCount":97},[],{"intervention":1811,"totalTrials":356,"cells":1812},"buprenorphine",{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1829},{"trials":1814,"activeCount":97},[],{"trials":1816,"activeCount":97},[],{"trials":1818,"activeCount":97},[],{"trials":1820,"activeCount":97},[],{"trials":1822,"activeCount":97},[1823],{"nctId":1824,"briefTitle":1825,"status":332,"phases":1826,"primaryCompletion":1169,"completion":1169,"start":1130,"enrollment":1207,"conditions":1827,"interventions":1828},"NCT00949299","Effects of Buprenorphine on Ulnar Nerve Motor Block",[89],[1700],[1811],{"trials":1830,"activeCount":97},[],{"intervention":1832,"totalTrials":356,"cells":1833},"folic acid 5mg\u002Fday",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1851},{"trials":1835,"activeCount":97},[],{"trials":1837,"activeCount":97},[],{"trials":1839,"activeCount":97},[],{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[1844],{"nctId":1845,"briefTitle":1846,"status":332,"phases":1847,"completion":1341,"start":1848,"conditions":1849,"interventions":1850},"NCT00491907","Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure",[89],"2004-10",[1209],[1832],{"trials":1852,"activeCount":97},[],{"intervention":1854,"totalTrials":356,"cells":1855},"oxygen inhalation",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1874},{"trials":1857,"activeCount":97},[],{"trials":1859,"activeCount":97},[],{"trials":1861,"activeCount":97},[],{"trials":1863,"activeCount":97},[],{"trials":1865,"activeCount":97},[1866],{"nctId":1867,"briefTitle":1868,"status":105,"phases":1869,"primaryCompletion":1064,"completion":1870,"start":1871,"enrollment":394,"conditions":1872,"interventions":1873},"NCT01057420","Effect of Hyperoxemia on Platelet Function in Healthy Volunteers",[89],"2010-05","2009-04",[1700],[1854],{"trials":1875,"activeCount":97},[],{"intervention":1877,"totalTrials":356,"cells":1878},"High-flow oxygen therapy",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1898},{"trials":1880,"activeCount":97},[],{"trials":1882,"activeCount":97},[],{"trials":1884,"activeCount":97},[],{"trials":1886,"activeCount":97},[],{"trials":1888,"activeCount":97},[1889],{"nctId":1890,"briefTitle":1891,"status":105,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1604,"conditions":1895,"interventions":1896},"NCT03955770","Effects of HFOT on Exercise Performance in Patients With COPD. A Randomized, Controlled Trial.",[89],"2019-08-02","2019-05-20",[27],[1877,1897],"Low-flow oxygen therapy",{"trials":1899,"activeCount":97},[],{"intervention":1897,"totalTrials":356,"cells":1901},{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1910,"NA":1916},{"trials":1903,"activeCount":97},[],{"trials":1905,"activeCount":97},[],{"trials":1907,"activeCount":97},[],{"trials":1909,"activeCount":97},[],{"trials":1911,"activeCount":97},[1912],{"nctId":1890,"briefTitle":1891,"status":105,"phases":1913,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1604,"conditions":1914,"interventions":1915},[89],[27],[1877,1897],{"trials":1917,"activeCount":97},[],{"intervention":1919,"totalTrials":356,"cells":1920},"Omeprazole",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1940},{"trials":1922,"activeCount":97},[],{"trials":1924,"activeCount":97},[],{"trials":1926,"activeCount":97},[],{"trials":1928,"activeCount":97},[],{"trials":1930,"activeCount":97},[1931],{"nctId":1932,"briefTitle":1933,"status":105,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1108,"enrollment":1936,"conditions":1937,"interventions":1939},"NCT02552537","iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions",[89],"2017-03",44,[1938],"Food Allergy",[1919],{"trials":1941,"activeCount":97},[],{"intervention":1257,"totalTrials":356,"cells":1943},{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1948,"PHASE3":1950,"PHASE4":1952,"NA":1958},{"trials":1945,"activeCount":97},[],{"trials":1947,"activeCount":97},[],{"trials":1949,"activeCount":97},[],{"trials":1951,"activeCount":97},[],{"trials":1953,"activeCount":97},[1954],{"nctId":1249,"briefTitle":1250,"status":119,"phases":1955,"primaryCompletion":1252,"completion":1252,"start":265,"enrollment":1253,"conditions":1956,"interventions":1957},[89],[1255],[1245,1257],{"trials":1959,"activeCount":97},[],{"intervention":1961,"totalTrials":356,"cells":1962},"Fluvastatin",{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1969,"PHASE4":1971,"NA":1985},{"trials":1964,"activeCount":97},[],{"trials":1966,"activeCount":97},[],{"trials":1968,"activeCount":97},[],{"trials":1970,"activeCount":97},[],{"trials":1972,"activeCount":97},[1973],{"nctId":1974,"briefTitle":1975,"status":105,"phases":1976,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":22,"conditions":1980,"interventions":1984},"NCT03189511","Effect of Fluvastatin on Brown Fat Activity",[89],"2018-01-23","2018-02-19","2017-05-31",[1981,1982,1983],"Adipose Tissue, Brown","Insulin Resistance","Clinical Trial",[1961],{"trials":1986,"activeCount":97},[],{"intervention":1988,"totalTrials":356,"cells":1989},"Apremilast 30mg",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2011},{"trials":1991,"activeCount":97},[],{"trials":1993,"activeCount":97},[],{"trials":1995,"activeCount":97},[],{"trials":1997,"activeCount":97},[],{"trials":1999,"activeCount":97},[2000],{"nctId":2001,"briefTitle":2002,"status":119,"phases":2003,"primaryCompletion":2004,"completion":2005,"start":2006,"enrollment":1143,"conditions":2007,"interventions":2010},"NCT03553433","Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis",[89],"2019-12","2020-06","2018-06",[2008,2009],"Psoriasis of Scalp","Psoriasis Vulgaris",[1988],{"trials":2012,"activeCount":97},[],{"intervention":2014,"totalTrials":356,"cells":2015},"Clevidipine",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2036},{"trials":2017,"activeCount":97},[],{"trials":2019,"activeCount":97},[],{"trials":2021,"activeCount":97},[],{"trials":2023,"activeCount":97},[],{"trials":2025,"activeCount":97},[2026],{"nctId":2027,"briefTitle":2028,"status":717,"phases":2029,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":97,"conditions":2032,"interventions":2034},"NCT03300479","Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)",[89],"2021-05-14","2017-06-15",[2033],"Nontraumatic Intracerebral Hemorrhage, Multiple Localized",[2014,2035],"Urapidil",{"trials":2037,"activeCount":97},[],{"intervention":2035,"totalTrials":356,"cells":2039},{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2046,"PHASE4":2048,"NA":2054},{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"trials":2045,"activeCount":97},[],{"trials":2047,"activeCount":97},[],{"trials":2049,"activeCount":97},[2050],{"nctId":2027,"briefTitle":2028,"status":717,"phases":2051,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":97,"conditions":2052,"interventions":2053},[89],[2033],[2014,2035],{"trials":2055,"activeCount":97},[],{"intervention":2057,"totalTrials":356,"cells":2058},"Supra- and subgingival rinsing with 10% PVP-iodine",{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2067,"NA":2077},{"trials":2060,"activeCount":97},[],{"trials":2062,"activeCount":97},[],{"trials":2064,"activeCount":97},[],{"trials":2066,"activeCount":97},[],{"trials":2068,"activeCount":97},[2069],{"nctId":2070,"briefTitle":2071,"status":105,"phases":2072,"primaryCompletion":2073,"completion":1551,"start":796,"enrollment":1207,"conditions":2074,"interventions":2076},"NCT01647347","PVP Iodine Effect on Post Debridement Bacteraemia",[89],"2013-07",[2075],"Bacteraemia Post Debridement",[2057],{"trials":2078,"activeCount":97},[],{"intervention":2080,"totalTrials":356,"cells":2081},"Vildagliptin",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2100},{"trials":2083,"activeCount":97},[],{"trials":2085,"activeCount":97},[],{"trials":2087,"activeCount":97},[],{"trials":2089,"activeCount":97},[],{"trials":2091,"activeCount":97},[2092],{"nctId":2093,"briefTitle":2094,"status":119,"phases":2095,"primaryCompletion":1252,"completion":1252,"start":2096,"enrollment":394,"conditions":2097,"interventions":2099},"NCT01426737","The Swiss Glucose Variability Study",[89],"2011-04",[2098],"Type 2 Diabetes",[2080],{"trials":2101,"activeCount":97},[],{"intervention":2103,"totalTrials":356,"cells":2104},"Discontinuation of Azathioprin",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2124},{"trials":2106,"activeCount":97},[],{"trials":2108,"activeCount":97},[],{"trials":2110,"activeCount":97},[],{"trials":2112,"activeCount":97},[],{"trials":2114,"activeCount":97},[2115],{"nctId":2116,"briefTitle":2117,"status":105,"phases":2118,"primaryCompletion":1340,"completion":2119,"start":2120,"enrollment":352,"conditions":2121,"interventions":2123},"NCT00492895","Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients",[89],"2011-03","2007-06",[2122],"Skin Cancer",[2103],{"trials":2125,"activeCount":97},[],{"intervention":1291,"totalTrials":356,"cells":2127},{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2136,"NA":2142},{"trials":2129,"activeCount":97},[],{"trials":2131,"activeCount":97},[],{"trials":2133,"activeCount":97},[],{"trials":2135,"activeCount":97},[],{"trials":2137,"activeCount":97},[2138],{"nctId":1283,"briefTitle":1284,"status":105,"phases":2139,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":394,"conditions":2140,"interventions":2141},[89],[1289],[1291,1292],{"trials":2143,"activeCount":97},[],{"intervention":2145,"totalTrials":356,"cells":2146},"Tranexamic Acid",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2164},{"trials":2148,"activeCount":97},[],{"trials":2150,"activeCount":97},[],{"trials":2152,"activeCount":97},[],{"trials":2154,"activeCount":97},[],{"trials":2156,"activeCount":97},[2157],{"nctId":2158,"briefTitle":2159,"status":119,"phases":2160,"primaryCompletion":1099,"completion":1099,"start":1168,"enrollment":394,"conditions":2161,"interventions":2163},"NCT02354885","TXA in the EMS on the Helicopter and the Ambulance",[89],[2162],"Bleeding",[2145],{"trials":2165,"activeCount":97},[],{"intervention":2167,"totalTrials":315,"cells":2168},"Vitamin D3",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2183,"PHASE4":2197,"NA":2199},{"trials":2170,"activeCount":97},[],{"trials":2172,"activeCount":97},[],{"trials":2174,"activeCount":97},[2175],{"nctId":2176,"briefTitle":2177,"status":105,"phases":2178,"primaryCompletion":2179,"completion":2179,"start":1252,"enrollment":629,"conditions":2180,"interventions":2182},"NCT01571063","Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D",[87],"2016-05",[2181],"Non-alcoholic Steatohepatitis (NASH)",[2167],{"trials":2184,"activeCount":97},[2185],{"nctId":2186,"briefTitle":2187,"status":105,"phases":2188,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":2192,"conditions":2193,"interventions":2195},"NCT01745263","DO-HEALTH \u002F Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial",[88],"2017-11-17","2018-01-19","2012-12-20",2157,[2194],"Improve Healthy Ageing in Seniors; Prevent Disease at Older Age",[2167,2196],"Omega 3 fatty acids",{"trials":2198,"activeCount":97},[],{"trials":2200,"activeCount":97},[],{"intervention":2202,"totalTrials":315,"cells":2203},"Abciximab",{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2228,"NA":2230},{"trials":2205,"activeCount":97},[],{"trials":2207,"activeCount":97},[],{"trials":2209,"activeCount":97},[],{"trials":2211,"activeCount":97},[2212,2221],{"nctId":2213,"briefTitle":2214,"status":332,"phases":2215,"completion":2216,"start":2217,"enrollment":124,"conditions":2218,"interventions":2220},"NCT00126139","Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis",[88],"2005-05","2004-04",[21,2219],"Stenosis",[2202],{"nctId":2222,"briefTitle":2223,"status":332,"phases":2224,"completion":2216,"start":2225,"enrollment":394,"conditions":2226,"interventions":2227},"NCT00167765","Abciximab in Wake-up Stroke",[88],"2005-03",[21],[2202],{"trials":2229,"activeCount":97},[],{"trials":2231,"activeCount":97},[],{"intervention":2233,"totalTrials":315,"cells":2234},"Vitamin D",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2247,"PHASE3":2249,"PHASE4":2258,"NA":2260},{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":97},[2239],{"nctId":2240,"briefTitle":2241,"status":105,"phases":2242,"primaryCompletion":2073,"completion":2073,"start":2243,"enrollment":36,"conditions":2244,"interventions":2246},"NCT01856348","Vitamin D3, Folic Acid and Fexofenadine in Healthy Volunteers",[86],"2013-05",[2245],"Physiological Effects of Vitamin D",[2233],{"trials":2248,"activeCount":97},[],{"trials":2250,"activeCount":97},[2251],{"nctId":2252,"briefTitle":2253,"status":105,"phases":2254,"primaryCompletion":1100,"completion":1314,"start":1672,"enrollment":451,"conditions":2255,"interventions":2257},"NCT02022475","Effect of Vitamin D Treatment on Fatigue",[88],[2256],"Vitamin D Deficiency",[2233],{"trials":2259,"activeCount":97},[],{"trials":2261,"activeCount":97},[],{"intervention":2263,"totalTrials":356,"cells":2264},"Dabigatran",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2288,"NA":2290},{"trials":2266,"activeCount":97},[],{"trials":2268,"activeCount":97},[],{"trials":2270,"activeCount":97},[],{"trials":2272,"activeCount":97},[2273],{"nctId":2274,"briefTitle":2275,"status":119,"phases":2276,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2283},"NCT03961334","MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention",[88],"2025-01-31","2026-01-31","2019-12-05",620,[2282],"Stroke, Ischemic",[2263,2284,2285,2286,2287],"Apixaban","Edoxaban","Aspirin","Clopidogrel",{"trials":2289,"activeCount":97},[],{"trials":2291,"activeCount":97},[],{"intervention":2284,"totalTrials":356,"cells":2293},{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2306,"NA":2308},{"trials":2295,"activeCount":97},[],{"trials":2297,"activeCount":97},[],{"trials":2299,"activeCount":97},[],{"trials":2301,"activeCount":97},[2302],{"nctId":2274,"briefTitle":2275,"status":119,"phases":2303,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2304,"interventions":2305},[88],[2282],[2263,2284,2285,2286,2287],{"trials":2307,"activeCount":97},[],{"trials":2309,"activeCount":97},[],{"intervention":2285,"totalTrials":356,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2324,"NA":2326},{"trials":2313,"activeCount":97},[],{"trials":2315,"activeCount":97},[],{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[2320],{"nctId":2274,"briefTitle":2275,"status":119,"phases":2321,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2322,"interventions":2323},[88],[2282],[2263,2284,2285,2286,2287],{"trials":2325,"activeCount":97},[],{"trials":2327,"activeCount":97},[],{"intervention":2286,"totalTrials":356,"cells":2329},{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2336,"PHASE4":2342,"NA":2344},{"trials":2331,"activeCount":97},[],{"trials":2333,"activeCount":97},[],{"trials":2335,"activeCount":97},[],{"trials":2337,"activeCount":97},[2338],{"nctId":2274,"briefTitle":2275,"status":119,"phases":2339,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2340,"interventions":2341},[88],[2282],[2263,2284,2285,2286,2287],{"trials":2343,"activeCount":97},[],{"trials":2345,"activeCount":97},[],{"intervention":2287,"totalTrials":356,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":97},[],{"trials":2351,"activeCount":97},[],{"trials":2353,"activeCount":97},[],{"trials":2355,"activeCount":97},[2356],{"nctId":2274,"briefTitle":2275,"status":119,"phases":2357,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2358,"interventions":2359},[88],[2282],[2263,2284,2285,2286,2287],{"trials":2361,"activeCount":97},[],{"trials":2363,"activeCount":97},[],{"intervention":2365,"totalTrials":356,"cells":2366},"Genipin",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2385,"NA":2387},{"trials":2368,"activeCount":97},[],{"trials":2370,"activeCount":97},[],{"trials":2372,"activeCount":97},[],{"trials":2374,"activeCount":97},[2375],{"nctId":2376,"briefTitle":2377,"status":105,"phases":2378,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2382,"interventions":2384},"NCT05755750","Intratendinous Genipin Injection in Horses With Tendon Injuries",[88],"2023-01-04","2016-06-28",74,[2383],"Superficial Digital Flexor Tendonitis",[2365],{"trials":2386,"activeCount":97},[],{"trials":2388,"activeCount":97},[],{"intervention":2390,"totalTrials":356,"cells":2391},"Pycnogenol®",{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2410,"NA":2412},{"trials":2393,"activeCount":97},[],{"trials":2395,"activeCount":97},[],{"trials":2397,"activeCount":97},[],{"trials":2399,"activeCount":97},[2400],{"nctId":2401,"briefTitle":2402,"status":105,"phases":2403,"primaryCompletion":2404,"completion":2277,"start":2405,"enrollment":606,"conditions":2406,"interventions":2409},"NCT05890534","Pycnogenol® in Post-COVID-19 Condition",[88],"2024-11-05","2023-06-07",[2407,2408],"Post COVID-19 Condition","Long COVID",[2390],{"trials":2411,"activeCount":97},[],{"trials":2413,"activeCount":97},[],{"intervention":2415,"totalTrials":356,"cells":2416},"osteoanabolic therapy",{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2423,"PHASE4":2433,"NA":2435},{"trials":2418,"activeCount":97},[],{"trials":2420,"activeCount":97},[],{"trials":2422,"activeCount":97},[],{"trials":2424,"activeCount":97},[2425],{"nctId":2426,"briefTitle":2427,"status":119,"phases":2428,"primaryCompletion":1312,"completion":2429,"start":756,"enrollment":36,"conditions":2430,"interventions":2432},"NCT01801397","A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)",[88],"2016-12",[2431],"Low Bone Mass in Anorexia Nervosa Patients",[2415],{"trials":2434,"activeCount":97},[],{"trials":2436,"activeCount":97},[],{"intervention":2438,"totalTrials":356,"cells":2439},"Surfactant nebulisation",{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2460,"NA":2462},{"trials":2441,"activeCount":97},[],{"trials":2443,"activeCount":97},[],{"trials":2445,"activeCount":97},[],{"trials":2447,"activeCount":97},[2448],{"nctId":2449,"briefTitle":2450,"status":105,"phases":2451,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":406,"conditions":2455,"interventions":2459},"NCT04315636","Surfactant Nebulization for the Early Aeration of the Preterm Lung",[88],"2021-11-01","2022-01-16","2021-03-19",[2456,2457,2458],"Preterm Birth","Respiratory Distress Syndrome","Surfactant Deficiency Syndrome Neonatal",[2438],{"trials":2461,"activeCount":97},[],{"trials":2463,"activeCount":97},[],{"intervention":740,"totalTrials":356,"cells":2465},{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2472,"PHASE4":2478,"NA":2480},{"trials":2467,"activeCount":97},[],{"trials":2469,"activeCount":97},[],{"trials":2471,"activeCount":97},[],{"trials":2473,"activeCount":97},[2474],{"nctId":729,"briefTitle":730,"status":105,"phases":2475,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":2476,"interventions":2477},[88],[737,738],[610,740],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"intervention":2483,"totalTrials":356,"cells":2484},"Phenobarbital",{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2503,"NA":2505},{"trials":2486,"activeCount":97},[],{"trials":2488,"activeCount":97},[],{"trials":2490,"activeCount":97},[],{"trials":2492,"activeCount":97},[2493],{"nctId":2494,"briefTitle":2495,"status":105,"phases":2496,"primaryCompletion":767,"completion":767,"start":2497,"enrollment":451,"conditions":2498,"interventions":2500},"NCT02810782","How to Treat Opiate Withdrawal in Neonates",[88],"2001-06",[2499],"Neonatal Abstinence Syndrome",[2483,2501,2502],"Chlorpromazine","Morphine",{"trials":2504,"activeCount":97},[],{"trials":2506,"activeCount":97},[],{"intervention":2501,"totalTrials":356,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2521,"NA":2523},{"trials":2510,"activeCount":97},[],{"trials":2512,"activeCount":97},[],{"trials":2514,"activeCount":97},[],{"trials":2516,"activeCount":97},[2517],{"nctId":2494,"briefTitle":2495,"status":105,"phases":2518,"primaryCompletion":767,"completion":767,"start":2497,"enrollment":451,"conditions":2519,"interventions":2520},[88],[2499],[2483,2501,2502],{"trials":2522,"activeCount":97},[],{"trials":2524,"activeCount":97},[],{"intervention":2502,"totalTrials":356,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2539,"NA":2541},{"trials":2528,"activeCount":97},[],{"trials":2530,"activeCount":97},[],{"trials":2532,"activeCount":97},[],{"trials":2534,"activeCount":97},[2535],{"nctId":2494,"briefTitle":2495,"status":105,"phases":2536,"primaryCompletion":767,"completion":767,"start":2497,"enrollment":451,"conditions":2537,"interventions":2538},[88],[2499],[2483,2501,2502],{"trials":2540,"activeCount":97},[],{"trials":2542,"activeCount":97},[],{"intervention":2544,"totalTrials":356,"cells":2545},"grazoprevir\u002Felbasvir, ribavirin",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2563,"NA":2565},{"trials":2547,"activeCount":97},[],{"trials":2549,"activeCount":97},[],{"trials":2551,"activeCount":97},[],{"trials":2553,"activeCount":97},[2554],{"nctId":2555,"briefTitle":2556,"status":105,"phases":2557,"primaryCompletion":755,"completion":2558,"start":1312,"enrollment":1315,"conditions":2559,"interventions":2562},"NCT02785666","Swiss HCVree Trial",[88],"2018-08",[2560,2561],"Hepatitis C","HIV",[2544],{"trials":2564,"activeCount":97},[],{"trials":2566,"activeCount":97},[],{"intervention":2196,"totalTrials":356,"cells":2568},{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2581,"NA":2583},{"trials":2570,"activeCount":97},[],{"trials":2572,"activeCount":97},[],{"trials":2574,"activeCount":97},[],{"trials":2576,"activeCount":97},[2577],{"nctId":2186,"briefTitle":2187,"status":105,"phases":2578,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":2192,"conditions":2579,"interventions":2580},[88],[2194],[2167,2196],{"trials":2582,"activeCount":97},[],{"trials":2584,"activeCount":97},[],{"intervention":2586,"totalTrials":356,"cells":2587},"Testosterone",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2594,"PHASE4":2607,"NA":2609},{"trials":2589,"activeCount":97},[],{"trials":2591,"activeCount":97},[],{"trials":2593,"activeCount":97},[],{"trials":2595,"activeCount":97},[2596],{"nctId":2597,"briefTitle":2598,"status":332,"phases":2599,"primaryCompletion":2600,"completion":2005,"start":1108,"enrollment":2601,"conditions":2602,"interventions":2605},"NCT02419105","Effects of Transdermal Testosterone and\u002For Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors",[88],"2020-05",91,[2603,2604],"Hypogonadism","Pre-frail Seniors",[2586,2606],"Colecalciferol",{"trials":2608,"activeCount":97},[],{"trials":2610,"activeCount":97},[],{"intervention":2606,"totalTrials":356,"cells":2612},{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2625,"NA":2627},{"trials":2614,"activeCount":97},[],{"trials":2616,"activeCount":97},[],{"trials":2618,"activeCount":97},[],{"trials":2620,"activeCount":97},[2621],{"nctId":2597,"briefTitle":2598,"status":332,"phases":2622,"primaryCompletion":2600,"completion":2005,"start":1108,"enrollment":2601,"conditions":2623,"interventions":2624},[88],[2603,2604],[2586,2606],{"trials":2626,"activeCount":97},[],{"trials":2628,"activeCount":97},[],{"intervention":2630,"totalTrials":356,"cells":2631},"Sirolimus",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2649,"NA":2651},{"trials":2633,"activeCount":97},[],{"trials":2635,"activeCount":97},[],{"trials":2637,"activeCount":97},[],{"trials":2639,"activeCount":97},[2640],{"nctId":2641,"briefTitle":2642,"status":105,"phases":2643,"primaryCompletion":1130,"completion":2644,"start":2645,"enrollment":124,"conditions":2646,"interventions":2648},"NCT00346918","Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[88],"2010-06","2006-06",[2647],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[2630],{"trials":2650,"activeCount":97},[],{"trials":2652,"activeCount":97},[],{"intervention":2654,"totalTrials":356,"cells":2655},"Enoxaparin 40Mg\u002F0.4Ml Inj Syringe 0.4Ml",{"EARLY_PHASE1":2656,"PHASE1":2658,"PHASE2":2660,"PHASE3":2662,"PHASE4":2676,"NA":2678},{"trials":2657,"activeCount":97},[],{"trials":2659,"activeCount":97},[],{"trials":2661,"activeCount":97},[],{"trials":2663,"activeCount":97},[2664],{"nctId":2665,"briefTitle":2666,"status":332,"phases":2667,"primaryCompletion":2668,"completion":2669,"start":2670,"enrollment":2671,"conditions":2672,"interventions":2675},"NCT04400799","Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19",[88],"2022-02-07","2022-04-12","2020-06-15",475,[2673,2674],"COVID-19","Pulmonary Embolism, Deep Vein Thrombosis",[2654],{"trials":2677,"activeCount":97},[],{"trials":2679,"activeCount":97},[],{"intervention":2681,"totalTrials":356,"cells":2682},"Ramipril",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2701,"NA":2703},{"trials":2684,"activeCount":97},[],{"trials":2686,"activeCount":97},[],{"trials":2688,"activeCount":97},[],{"trials":2690,"activeCount":97},[2691],{"nctId":2692,"briefTitle":2693,"status":105,"phases":2694,"completion":2695,"start":2696,"enrollment":2697,"conditions":2698,"interventions":2700},"NCT00273533","Ramipril in Rheumatoid Arthritis",[87,88],"2006-07","2004-06",13,[2699],"Arthritis, Rheumatoid",[2681],{"trials":2702,"activeCount":97},[],{"trials":2704,"activeCount":97},[],{"intervention":2706,"totalTrials":356,"cells":2707},"injections",{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2714,"PHASE4":2725,"NA":2727},{"trials":2709,"activeCount":97},[],{"trials":2711,"activeCount":97},[],{"trials":2713,"activeCount":97},[],{"trials":2715,"activeCount":97},[2716],{"nctId":2717,"briefTitle":2718,"status":105,"phases":2719,"primaryCompletion":2720,"completion":2721,"start":1721,"enrollment":22,"conditions":2722,"interventions":2724},"NCT01333293","The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients",[87,88],"2015-10","2016-01",[2723],"Mastocytosis",[2706],{"trials":2726,"activeCount":97},[],{"trials":2728,"activeCount":97},[],{"intervention":2730,"totalTrials":356,"cells":2731},"Application of Tralokinumab",{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2738,"PHASE4":2749,"NA":2751},{"trials":2733,"activeCount":97},[],{"trials":2735,"activeCount":97},[],{"trials":2737,"activeCount":97},[],{"trials":2739,"activeCount":97},[2740],{"nctId":2741,"briefTitle":2742,"status":332,"phases":2743,"primaryCompletion":2744,"completion":2744,"start":2745,"enrollment":19,"conditions":2746,"interventions":2748},"NCT05378698","Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation",[87,88],"2025-03-04","2022-06-15",[2747],"Atopic Dermatitis",[2730],{"trials":2750,"activeCount":97},[],{"trials":2752,"activeCount":97},[],{"intervention":2754,"totalTrials":356,"cells":2755},"Flutemetamol",{"EARLY_PHASE1":2756,"PHASE1":2758,"PHASE2":2760,"PHASE3":2762,"PHASE4":2774,"NA":2776},{"trials":2757,"activeCount":97},[],{"trials":2759,"activeCount":97},[],{"trials":2761,"activeCount":97},[],{"trials":2763,"activeCount":97},[2764],{"nctId":2765,"briefTitle":2766,"status":332,"phases":2767,"primaryCompletion":2768,"completion":2768,"start":1100,"enrollment":33,"conditions":2769,"interventions":2773},"NCT02353949","Investigating the Clinical Consequences of Flutemetamol-PET-scanning",[88],"2019-12-10",[2770,2771,2772],"Mild Cognitive Impairment","Alzheimer's Disease","Dementia",[2754],{"trials":2775,"activeCount":97},[],{"trials":2777,"activeCount":97},[],{"intervention":2779,"totalTrials":356,"cells":2780},"Omegaven™",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2787,"PHASE4":2798,"NA":2800},{"trials":2782,"activeCount":97},[],{"trials":2784,"activeCount":97},[],{"trials":2786,"activeCount":97},[],{"trials":2788,"activeCount":97},[2789],{"nctId":2790,"briefTitle":2791,"status":119,"phases":2792,"primaryCompletion":2793,"completion":2793,"start":2073,"enrollment":2794,"conditions":2795,"interventions":2797},"NCT01884948","Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection",[88],"2016-03",258,[2796],"Major Liver Surgery",[2779],{"trials":2799,"activeCount":97},[],{"trials":2801,"activeCount":97},[],{"intervention":2803,"totalTrials":356,"cells":2804},"Neoadjuvant Chemotherapy with gemcitabine\u002Foxaliplatin",{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2811,"PHASE4":2825,"NA":2827},{"trials":2806,"activeCount":97},[],{"trials":2808,"activeCount":97},[],{"trials":2810,"activeCount":97},[],{"trials":2812,"activeCount":97},[2813],{"nctId":2814,"briefTitle":2815,"status":332,"phases":2816,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2823},"NCT01314027","Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer",[88],"2018-12","2019-05","2009-09",38,[2822],"Pancreatic Cancer",[2803,2824],"adjuvant chemotherapy with gemcitabine",{"trials":2826,"activeCount":97},[],{"trials":2828,"activeCount":97},[],{"intervention":2824,"totalTrials":356,"cells":2830},{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2837,"PHASE4":2843,"NA":2845},{"trials":2832,"activeCount":97},[],{"trials":2834,"activeCount":97},[],{"trials":2836,"activeCount":97},[],{"trials":2838,"activeCount":97},[2839],{"nctId":2814,"briefTitle":2815,"status":332,"phases":2840,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":2841,"interventions":2842},[88],[2822],[2803,2824],{"trials":2844,"activeCount":97},[],{"trials":2846,"activeCount":97},[],{"intervention":2848,"totalTrials":356,"cells":2849},"MMR booster vaccination",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2856,"PHASE4":2871,"NA":2873},{"trials":2851,"activeCount":97},[],{"trials":2853,"activeCount":97},[],{"trials":2855,"activeCount":97},[],{"trials":2857,"activeCount":97},[2858],{"nctId":2859,"briefTitle":2860,"status":119,"phases":2861,"primaryCompletion":2862,"completion":2863,"start":2864,"enrollment":2865,"conditions":2866,"interventions":2870},"NCT05894395","Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination",[88],"2025-03-01","2025-09-01","2023-12-01",200,[2867,2868,2869],"Mumps","Measles","Rubella",[2848],{"trials":2872,"activeCount":97},[],{"trials":2874,"activeCount":97},[],{"intervention":2876,"totalTrials":356,"cells":2877},"InductOs",{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2884,"PHASE4":2895,"NA":2897},{"trials":2879,"activeCount":97},[],{"trials":2881,"activeCount":97},[],{"trials":2883,"activeCount":97},[],{"trials":2885,"activeCount":97},[2886],{"nctId":2887,"briefTitle":2888,"status":105,"phases":2889,"primaryCompletion":2890,"completion":2891,"start":1645,"enrollment":19,"conditions":2892,"interventions":2894},"NCT01541345","Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2",[88],"2014-04-25","2019-06-04",[2893],"Missing Teeth",[2876],{"trials":2896,"activeCount":97},[],{"trials":2898,"activeCount":97},[],{"intervention":2900,"totalTrials":315,"cells":2901},"Polvac Grass+Rye",{"EARLY_PHASE1":2902,"PHASE1":2917,"PHASE2":2919,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2903,"activeCount":97},[2904],{"nctId":2905,"briefTitle":2906,"status":105,"phases":2907,"primaryCompletion":2908,"completion":2909,"start":2910,"enrollment":1240,"conditions":2911,"interventions":2916},"NCT05960266","Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study",[85],"2024-04-14","2024-06-01","2023-11-23",[2912,2913,2914,2915],"Hypersensitivity","Hay Fever","Rhinitis, Allergic, Seasonal","Rhinoconjunctivitis",[2900],{"trials":2918,"activeCount":97},[],{"trials":2920,"activeCount":97},[2921],{"nctId":2922,"briefTitle":2923,"status":105,"phases":2924,"primaryCompletion":2925,"completion":2925,"start":2926,"enrollment":2927,"conditions":2928,"interventions":2931},"NCT05297760","Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract",[86,87],"2025-02-28","2022-02-10",60,[2914,2929,501,2930,502],"Rhinitis; Allergic, With Asthma","Allergic Rhinitis Due to Grass Pollen",[2900,2932],"Saline 0.9%",{"trials":2934,"activeCount":97},[],{"trials":2936,"activeCount":97},[],{"trials":2938,"activeCount":97},[],{"intervention":2940,"totalTrials":315,"cells":2941},"Canakinumab",{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2943,"activeCount":97},[],{"trials":2945,"activeCount":97},[],{"trials":2947,"activeCount":97},[2948,2957],{"nctId":2949,"briefTitle":2950,"status":119,"phases":2951,"primaryCompletion":2429,"completion":2952,"start":2953,"enrollment":1207,"conditions":2954,"interventions":2956},"NCT01635127","Efficacy Study of Canakinumab to Treat Urticaria",[87],"2017-05","2012-06",[2955],"Chronic Idiopathic Urticaria",[2940],{"nctId":2958,"briefTitle":2959,"status":105,"phases":2960,"primaryCompletion":2961,"completion":2962,"start":1645,"enrollment":361,"conditions":2963,"interventions":2965},"NCT01302795","Canakinumab for Pyoderma Gangrenosum",[87],"2014-08","2015-11",[2964],"Pyoderma Gangrenosum",[2940],{"trials":2967,"activeCount":97},[],{"trials":2969,"activeCount":97},[],{"trials":2971,"activeCount":97},[],{"intervention":2973,"totalTrials":315,"cells":2974},"Psilocybin",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2990,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2976,"activeCount":97},[],{"trials":2978,"activeCount":97},[2979],{"nctId":2980,"briefTitle":2981,"status":105,"phases":2982,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":2985,"conditions":2986,"interventions":2987},"NCT06081179","Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans",[86],"2025-09-22","2023-10-24",122,[15],[2973,2988,2989],"3,4 Methylenedioxymethamphetamine","Methylphenidate",{"trials":2991,"activeCount":97},[2992],{"nctId":2993,"briefTitle":2994,"status":105,"phases":2995,"primaryCompletion":2996,"completion":2997,"start":2998,"enrollment":1132,"conditions":2999,"interventions":3001},"NCT04141501","Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients",[87],"2023-03-14","2023-09-14","2020-06-08",[3000],"Alcohol Use Disorder",[2973],{"trials":3003,"activeCount":97},[],{"trials":3005,"activeCount":97},[],{"trials":3007,"activeCount":97},[],{"intervention":3009,"totalTrials":356,"cells":3010},"Standardized anthocyanin-rich extract",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3012,"activeCount":97},[],{"trials":3014,"activeCount":97},[],{"trials":3016,"activeCount":97},[3017],{"nctId":3018,"briefTitle":3019,"status":105,"phases":3020,"primaryCompletion":3021,"completion":3021,"start":3022,"enrollment":1253,"conditions":3023,"interventions":3025},"NCT04000139","Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis",[87],"2021-03-11","2019-04-01",[3024],"Ulcerative Colitis",[3009],{"trials":3027,"activeCount":97},[],{"trials":3029,"activeCount":97},[],{"trials":3031,"activeCount":97},[],{"intervention":3033,"totalTrials":356,"cells":3034},"retroviral SF71-gp91phox transduced CD34+ cells",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3036,"activeCount":97},[],{"trials":3038,"activeCount":97},[],{"trials":3040,"activeCount":97},[3041],{"nctId":3042,"briefTitle":3043,"status":105,"phases":3044,"primaryCompletion":1340,"completion":1721,"start":2696,"enrollment":315,"conditions":3045,"interventions":3047},"NCT00927134","Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children",[86,87],[3046],"Chronic Granulomatous Disease",[3033],{"trials":3049,"activeCount":97},[],{"trials":3051,"activeCount":97},[],{"trials":3053,"activeCount":97},[],{"intervention":3055,"totalTrials":356,"cells":3056},"Cisplatin and Gemcitabine",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3058,"activeCount":97},[],{"trials":3060,"activeCount":97},[],{"trials":3062,"activeCount":97},[3063],{"nctId":3064,"briefTitle":3065,"status":105,"phases":3066,"primaryCompletion":1550,"completion":1550,"start":1339,"enrollment":153,"conditions":3067,"interventions":3069},"NCT01073839","Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.",[86,87],[3068],"Cholangiocellular Carcinoma",[3055],{"trials":3071,"activeCount":97},[],{"trials":3073,"activeCount":97},[],{"trials":3075,"activeCount":97},[],{"intervention":3077,"totalTrials":356,"cells":3078},"intracavitary cisplatin-fibrin",{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3095,"PHASE4":3097,"NA":3099},{"trials":3080,"activeCount":97},[],{"trials":3082,"activeCount":97},[],{"trials":3084,"activeCount":97},[3085],{"nctId":3086,"briefTitle":3087,"status":105,"phases":3088,"primaryCompletion":2004,"completion":3089,"start":3090,"enrollment":3091,"conditions":3092,"interventions":3094},"NCT01644994","Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P\u002FD or EPP for Malignant Pleural Mesothelioma",[86,87],"2021-08","2012-11",47,[3093],"Malignant Pleural Mesothelioma",[3077],{"trials":3096,"activeCount":97},[],{"trials":3098,"activeCount":97},[],{"trials":3100,"activeCount":97},[],{"intervention":446,"totalTrials":356,"cells":3102},{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3107,"PHASE3":3113,"PHASE4":3115,"NA":3117},{"trials":3104,"activeCount":97},[],{"trials":3106,"activeCount":97},[],{"trials":3108,"activeCount":97},[3109],{"nctId":437,"briefTitle":438,"status":119,"phases":3110,"completion":440,"start":441,"enrollment":442,"conditions":3111,"interventions":3112},[87],[444],[428,446],{"trials":3114,"activeCount":97},[],{"trials":3116,"activeCount":97},[],{"trials":3118,"activeCount":97},[],{"intervention":2932,"totalTrials":356,"cells":3120},{"EARLY_PHASE1":3121,"PHASE1":3123,"PHASE2":3125,"PHASE3":3131,"PHASE4":3133,"NA":3135},{"trials":3122,"activeCount":97},[],{"trials":3124,"activeCount":97},[],{"trials":3126,"activeCount":97},[3127],{"nctId":2922,"briefTitle":2923,"status":105,"phases":3128,"primaryCompletion":2925,"completion":2925,"start":2926,"enrollment":2927,"conditions":3129,"interventions":3130},[86,87],[2914,2929,501,2930,502],[2900,2932],{"trials":3132,"activeCount":97},[],{"trials":3134,"activeCount":97},[],{"trials":3136,"activeCount":97},[],{"intervention":3138,"totalTrials":356,"cells":3139},"Terlipressin",{"EARLY_PHASE1":3140,"PHASE1":3142,"PHASE2":3144,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3141,"activeCount":97},[],{"trials":3143,"activeCount":97},[],{"trials":3145,"activeCount":97},[3146],{"nctId":3147,"briefTitle":3148,"status":717,"phases":3149,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":97,"conditions":3152,"interventions":3154},"NCT02368249","Does Terlipressin Improve Renal Outcome After Liver Surgery",[87],"2025-02","2020-01",[3153],"Kidney Failure",[3138],{"trials":3156,"activeCount":97},[],{"trials":3158,"activeCount":97},[],{"trials":3160,"activeCount":97},[],{"intervention":3162,"totalTrials":356,"cells":3163},"Cetuximab",{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3168,"PHASE3":3181,"PHASE4":3183,"NA":3185},{"trials":3165,"activeCount":97},[],{"trials":3167,"activeCount":97},[],{"trials":3169,"activeCount":97},[3170],{"nctId":3171,"briefTitle":3172,"status":105,"phases":3173,"primaryCompletion":3174,"completion":3174,"start":3175,"enrollment":735,"conditions":3176,"interventions":3180},"NCT01435252","A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab",[87],"2017-10-25","2011-09-19",[3177,3178,3179],"Oropharyngeal Cancer","Hypopharyngeal Cancer","Laryngeal Cancer",[3162],{"trials":3182,"activeCount":97},[],{"trials":3184,"activeCount":97},[],{"trials":3186,"activeCount":97},[],{"intervention":3188,"totalTrials":356,"cells":3189},"Gefitnib",{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3191,"activeCount":97},[],{"trials":3193,"activeCount":97},[],{"trials":3195,"activeCount":97},[3196],{"nctId":3197,"briefTitle":3198,"status":105,"phases":3199,"completion":1341,"start":3200,"enrollment":629,"conditions":3201,"interventions":3203},"NCT00250887","Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research",[87],"2005-07",[3202],"Recurrent Glioblastoma",[3188],{"trials":3205,"activeCount":97},[],{"trials":3207,"activeCount":97},[],{"trials":3209,"activeCount":97},[],{"intervention":3211,"totalTrials":356,"cells":3212},"Aspirin 100mg",{"EARLY_PHASE1":3213,"PHASE1":3215,"PHASE2":3217,"PHASE3":3230,"PHASE4":3232,"NA":3234},{"trials":3214,"activeCount":97},[],{"trials":3216,"activeCount":97},[],{"trials":3218,"activeCount":97},[3219],{"nctId":3220,"briefTitle":3221,"status":332,"phases":3222,"primaryCompletion":3223,"completion":3223,"start":3224,"enrollment":3225,"conditions":3226,"interventions":3229},"NCT04128956","Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS",[87],"2024-02-21","2020-03-11",172,[3227,3228],"Venous Thromboses","Stent Stenosis",[3211],{"trials":3231,"activeCount":97},[],{"trials":3233,"activeCount":97},[],{"trials":3235,"activeCount":97},[],{"intervention":3237,"totalTrials":356,"cells":3238},"Gemcitabine \u002F Cisplatin",{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3254,"PHASE4":3256,"NA":3258},{"trials":3240,"activeCount":97},[],{"trials":3242,"activeCount":97},[],{"trials":3244,"activeCount":97},[3245],{"nctId":3246,"briefTitle":3247,"status":105,"phases":3248,"completion":1341,"start":3249,"enrollment":3250,"conditions":3251,"interventions":3253},"NCT00490360","Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head",[87],"2001-10",2007,[3252],"Cancer of the Pancreatic Head",[3237],{"trials":3255,"activeCount":97},[],{"trials":3257,"activeCount":97},[],{"trials":3259,"activeCount":97},[],{"intervention":3261,"totalTrials":356,"cells":3262},"Lidocaine and sodium bicarbonate",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3264,"activeCount":97},[],{"trials":3266,"activeCount":97},[],{"trials":3268,"activeCount":97},[3269],{"nctId":3270,"briefTitle":3271,"status":105,"phases":3272,"primaryCompletion":3273,"completion":3273,"start":3274,"enrollment":1253,"conditions":3275,"interventions":3278},"NCT03238625","Painless Local Anaesthesia With Bicarbonate Admixture",[87],"2017-10-18","2017-08-01",[3276,3277],"Local Infiltration","Anesthesia",[3261,3261,3279,3280],"Lidocaine","Sodium cloride 0.9%",{"trials":3282,"activeCount":97},[],{"trials":3284,"activeCount":97},[],{"trials":3286,"activeCount":97},[],{"intervention":3279,"totalTrials":356,"cells":3288},{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3293,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3290,"activeCount":97},[],{"trials":3292,"activeCount":97},[],{"trials":3294,"activeCount":97},[3295],{"nctId":3270,"briefTitle":3271,"status":105,"phases":3296,"primaryCompletion":3273,"completion":3273,"start":3274,"enrollment":1253,"conditions":3297,"interventions":3298},[87],[3276,3277],[3261,3261,3279,3280],{"trials":3300,"activeCount":97},[],{"trials":3302,"activeCount":97},[],{"trials":3304,"activeCount":97},[],{"intervention":3280,"totalTrials":356,"cells":3306},{"EARLY_PHASE1":3307,"PHASE1":3309,"PHASE2":3311,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3308,"activeCount":97},[],{"trials":3310,"activeCount":97},[],{"trials":3312,"activeCount":97},[3313],{"nctId":3270,"briefTitle":3271,"status":105,"phases":3314,"primaryCompletion":3273,"completion":3273,"start":3274,"enrollment":1253,"conditions":3315,"interventions":3316},[87],[3276,3277],[3261,3261,3279,3280],{"trials":3318,"activeCount":97},[],{"trials":3320,"activeCount":97},[],{"trials":3322,"activeCount":97},[],{"intervention":3324,"totalTrials":356,"cells":3325},"autologous muscle precursor cells",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3327,"activeCount":97},[],{"trials":3329,"activeCount":97},[],{"trials":3331,"activeCount":97},[3332],{"nctId":3333,"briefTitle":3334,"status":105,"phases":3335,"primaryCompletion":3336,"completion":3336,"start":3337,"enrollment":415,"conditions":3338,"interventions":3340},"NCT05534269","Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy",[87],"2025-07-14","2022-10-17",[3339],"Female Stress Urinary Incontinence",[3324],{"trials":3342,"activeCount":97},[],{"trials":3344,"activeCount":97},[],{"trials":3346,"activeCount":97},[],{"intervention":3348,"totalTrials":356,"cells":3349},"Erythropoietin",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3363,"PHASE4":3365,"NA":3367},{"trials":3351,"activeCount":97},[],{"trials":3353,"activeCount":97},[],{"trials":3355,"activeCount":97},[3356],{"nctId":3357,"briefTitle":3358,"status":119,"phases":3359,"primaryCompletion":3360,"completion":1672,"start":1459,"enrollment":406,"conditions":3361,"interventions":3362},"NCT01889056","Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans",[86,87],"2013-09",[15],[3348],{"trials":3364,"activeCount":97},[],{"trials":3366,"activeCount":97},[],{"trials":3368,"activeCount":97},[],{"intervention":3370,"totalTrials":356,"cells":3371},"XOMA 052",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3373,"activeCount":97},[],{"trials":3375,"activeCount":97},[],{"trials":3377,"activeCount":97},[3378],{"nctId":3379,"briefTitle":3380,"status":105,"phases":3381,"primaryCompletion":3360,"completion":3360,"start":2819,"enrollment":629,"conditions":3382,"interventions":3384},"NCT01788033","Effects of XOMA 052 on Insulin Production in Type 1 Diabetes",[87],[3383],"Diabetes Mellitus Type 1",[3370],{"trials":3386,"activeCount":97},[],{"trials":3388,"activeCount":97},[],{"trials":3390,"activeCount":97},[],{"intervention":3392,"totalTrials":356,"cells":3393},"Pazopanib\u002FPaclitaxel",{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3395,"activeCount":97},[],{"trials":3397,"activeCount":97},[],{"trials":3399,"activeCount":97},[3400],{"nctId":3401,"briefTitle":3402,"status":105,"phases":3403,"primaryCompletion":3404,"completion":1100,"start":796,"enrollment":3405,"conditions":3406,"interventions":3408},"NCT01666418","Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel",[87],"2014-10",19,[3407],"Melanoma",[3392],{"trials":3410,"activeCount":97},[],{"trials":3412,"activeCount":97},[],{"trials":3414,"activeCount":97},[],{"intervention":3416,"totalTrials":356,"cells":3417},"Zostavax",{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3431,"PHASE4":3433,"NA":3435},{"trials":3419,"activeCount":97},[],{"trials":3421,"activeCount":97},[],{"trials":3423,"activeCount":97},[3424],{"nctId":3425,"briefTitle":3426,"status":717,"phases":3427,"primaryCompletion":1169,"completion":2953,"start":1340,"enrollment":97,"conditions":3428,"interventions":3430},"NCT01213810","Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study",[86,87],[3429],"Herpes Zoster",[3416],{"trials":3432,"activeCount":97},[],{"trials":3434,"activeCount":97},[],{"trials":3436,"activeCount":97},[],{"intervention":3438,"totalTrials":356,"cells":3439},"Potassium citrate",{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3444,"PHASE3":3458,"PHASE4":3460,"NA":3462},{"trials":3441,"activeCount":97},[],{"trials":3443,"activeCount":97},[],{"trials":3445,"activeCount":97},[3446],{"nctId":3447,"briefTitle":3448,"status":105,"phases":3449,"primaryCompletion":1064,"completion":1064,"start":767,"enrollment":415,"conditions":3450,"interventions":3456},"NCT00913796","Metabolic Acidosis in Renal Transplant Patients",[87],[3451,3452,3453,3454,3455],"Renal Transplant Patients","Metabolic Acidosis","Physical Capacity","Bone Disease","Mineral Metabolism",[3438,3457],"Potassium chloride",{"trials":3459,"activeCount":97},[],{"trials":3461,"activeCount":97},[],{"trials":3463,"activeCount":97},[],{"intervention":3457,"totalTrials":356,"cells":3465},{"EARLY_PHASE1":3466,"PHASE1":3468,"PHASE2":3470,"PHASE3":3476,"PHASE4":3478,"NA":3480},{"trials":3467,"activeCount":97},[],{"trials":3469,"activeCount":97},[],{"trials":3471,"activeCount":97},[3472],{"nctId":3447,"briefTitle":3448,"status":105,"phases":3473,"primaryCompletion":1064,"completion":1064,"start":767,"enrollment":415,"conditions":3474,"interventions":3475},[87],[3451,3452,3453,3454,3455],[3438,3457],{"trials":3477,"activeCount":97},[],{"trials":3479,"activeCount":97},[],{"trials":3481,"activeCount":97},[],{"intervention":3483,"totalTrials":356,"cells":3484},"18F-PSS232",{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3486,"activeCount":97},[],{"trials":3488,"activeCount":97},[],{"trials":3490,"activeCount":97},[3491],{"nctId":3492,"briefTitle":3493,"status":332,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":1549,"enrollment":36,"conditions":3496,"interventions":3497},"NCT02511691","PET\u002FMRI Imaging of Glutamate Release in the Brain",[87],"2016-03-03",[15],[3483],{"trials":3499,"activeCount":97},[],{"trials":3501,"activeCount":97},[],{"trials":3503,"activeCount":97},[],{"intervention":3505,"totalTrials":356,"cells":3506},"Intravenous Silibinin",{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3508,"activeCount":97},[],{"trials":3510,"activeCount":97},[],{"trials":3512,"activeCount":97},[3513],{"nctId":3514,"briefTitle":3515,"status":105,"phases":3516,"primaryCompletion":3517,"completion":1168,"start":3518,"enrollment":1207,"conditions":3519,"interventions":3520},"NCT01816490","THISTLE - The HIV-HCV Silibinin Trial",[87],"2014-04","2013-04",[2561,2560],[3505],{"trials":3522,"activeCount":97},[],{"trials":3524,"activeCount":97},[],{"trials":3526,"activeCount":97},[],{"intervention":3528,"totalTrials":356,"cells":3529},"Rufinamide",{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3544,"PHASE4":3546,"NA":3548},{"trials":3531,"activeCount":97},[],{"trials":3533,"activeCount":97},[],{"trials":3535,"activeCount":97},[3536],{"nctId":3537,"briefTitle":3538,"status":717,"phases":3539,"primaryCompletion":1100,"completion":1100,"start":756,"enrollment":97,"conditions":3540,"interventions":3543},"NCT02095899","Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome",[87],[3541,3542],"Peripheral Nerve Injuries","Pain",[3528],{"trials":3545,"activeCount":97},[],{"trials":3547,"activeCount":97},[],{"trials":3549,"activeCount":97},[],{"intervention":3551,"totalTrials":356,"cells":3552},"Allergen specific immunotherapy",{"EARLY_PHASE1":3553,"PHASE1":3555,"PHASE2":3557,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3554,"activeCount":97},[],{"trials":3556,"activeCount":97},[],{"trials":3558,"activeCount":97},[3559],{"nctId":3560,"briefTitle":3561,"status":105,"phases":3562,"completion":2225,"start":2497,"enrollment":3563,"conditions":3564,"interventions":3566},"NCT00470457","A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy",[87],156,[3565],"Rhinoconjunctivitis Due to Grass Pollen Allergy",[3551],{"trials":3568,"activeCount":97},[],{"trials":3570,"activeCount":97},[],{"trials":3572,"activeCount":97},[],{"intervention":3574,"totalTrials":356,"cells":3575},"Ointment",{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3589,"PHASE4":3591,"NA":3593},{"trials":3577,"activeCount":97},[],{"trials":3579,"activeCount":97},[],{"trials":3581,"activeCount":97},[3582],{"nctId":3583,"briefTitle":3584,"status":105,"phases":3585,"primaryCompletion":1870,"completion":1696,"start":1871,"enrollment":442,"conditions":3586,"interventions":3588},"NCT00914745","Place Controlled Study to Treat Recurrent Herpes Labialis.",[87],[3587],"Recurrent Herpes Labialis",[3574],{"trials":3590,"activeCount":97},[],{"trials":3592,"activeCount":97},[],{"trials":3594,"activeCount":97},[],{"intervention":3596,"totalTrials":356,"cells":3597},"Oxycarbon",{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":97},[],{"trials":3603,"activeCount":97},[3604],{"nctId":3605,"briefTitle":3606,"status":105,"phases":3607,"primaryCompletion":3608,"completion":3609,"start":3610,"enrollment":415,"conditions":3611,"interventions":3613},"NCT03338907","CO2 (Carbon Dioxide) - Cerebral Oxygenation",[87],"2018-10-26","2019-02-12","2018-01-25",[3612],"Hypoxia, Brain",[3596],{"trials":3615,"activeCount":97},[],{"trials":3617,"activeCount":97},[],{"trials":3619,"activeCount":97},[],{"intervention":3621,"totalTrials":356,"cells":3622},"IL-1Ra",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3636,"PHASE4":3638,"NA":3640},{"trials":3624,"activeCount":97},[],{"trials":3626,"activeCount":97},[],{"trials":3628,"activeCount":97},[3629],{"nctId":3630,"briefTitle":3631,"status":105,"phases":3632,"completion":768,"start":2217,"enrollment":3633,"conditions":3634,"interventions":3635},"NCT00303394","Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist",[87],72,[2098],[3621],{"trials":3637,"activeCount":97},[],{"trials":3639,"activeCount":97},[],{"trials":3641,"activeCount":97},[],{"intervention":3643,"totalTrials":356,"cells":3644},"Application of SHB001",{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3659,"PHASE4":3661,"NA":3663},{"trials":3646,"activeCount":97},[],{"trials":3648,"activeCount":97},[],{"trials":3650,"activeCount":97},[3651],{"nctId":3652,"briefTitle":3653,"status":105,"phases":3654,"primaryCompletion":108,"completion":108,"start":3655,"enrollment":406,"conditions":3656,"interventions":3658},"NCT01243008","Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation",[86,87],"2010-04",[3657],"Lyme Disease",[3643],{"trials":3660,"activeCount":97},[],{"trials":3662,"activeCount":97},[],{"trials":3664,"activeCount":97},[],{"intervention":3666,"totalTrials":356,"cells":3667},"NG-101",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3685,"PHASE4":3687,"NA":3689},{"trials":3669,"activeCount":97},[],{"trials":3671,"activeCount":97},[],{"trials":3673,"activeCount":97},[3674],{"nctId":3675,"briefTitle":3676,"status":105,"phases":3677,"primaryCompletion":3678,"completion":3678,"start":3679,"enrollment":3680,"conditions":3681,"interventions":3683},"NCT03935321","NISCI - Nogo Inhibition in Spinal Cord Injury",[87],"2023-02-02","2019-05-15",129,[3682],"Spinal Cord Injury, Acute",[3666,3684],"Placebos",{"trials":3686,"activeCount":97},[],{"trials":3688,"activeCount":97},[],{"trials":3690,"activeCount":97},[],{"intervention":3692,"totalTrials":356,"cells":3693},"Memantinhydrochlorid",{"EARLY_PHASE1":3694,"PHASE1":3696,"PHASE2":3698,"PHASE3":3709,"PHASE4":3711,"NA":3713},{"trials":3695,"activeCount":97},[],{"trials":3697,"activeCount":97},[],{"trials":3699,"activeCount":97},[3700],{"nctId":3701,"briefTitle":3702,"status":105,"phases":3703,"primaryCompletion":3704,"completion":3705,"start":1550,"enrollment":337,"conditions":3706,"interventions":3708},"NCT02615847","Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients",[87],"2017-03-31","2017-07",[3707],"Sickle Cell Disease",[3692],{"trials":3710,"activeCount":97},[],{"trials":3712,"activeCount":97},[],{"trials":3714,"activeCount":97},[],{"intervention":3716,"totalTrials":356,"cells":3717},"Sorafenib",{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3719,"activeCount":97},[],{"trials":3721,"activeCount":97},[],{"trials":3723,"activeCount":97},[3724],{"nctId":3725,"briefTitle":3726,"status":105,"phases":3727,"primaryCompletion":265,"completion":1130,"start":235,"enrollment":1646,"conditions":3728,"interventions":3731},"NCT00794235","Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine",[87],[3729,3730],"Melanoma Stage III or IV","No Prior Chemotherapy",[3716],{"trials":3733,"activeCount":97},[],{"trials":3735,"activeCount":97},[],{"trials":3737,"activeCount":97},[],{"intervention":3739,"totalTrials":356,"cells":3740},"Hidroferol®",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3742,"activeCount":97},[],{"trials":3744,"activeCount":97},[],{"trials":3746,"activeCount":97},[3747],{"nctId":3748,"briefTitle":3749,"status":105,"phases":3750,"primaryCompletion":3751,"completion":1169,"start":1130,"enrollment":2865,"conditions":3752,"interventions":3755},"NCT01017354","Zurich Disability Prevention Trial",[87],"2011-11",[3753,3754],"Community-dwelling Seniors","History of a Fall in the Previous 12 Months",[3739],{"trials":3757,"activeCount":97},[],{"trials":3759,"activeCount":97},[],{"trials":3761,"activeCount":97},[],{"intervention":3763,"totalTrials":356,"cells":3764},"Purified allergen dose 1 integrated in a Patch system",{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3783,"PHASE4":3785,"NA":3787},{"trials":3766,"activeCount":97},[],{"trials":3768,"activeCount":97},[],{"trials":3770,"activeCount":97},[3771],{"nctId":3772,"briefTitle":3773,"status":105,"phases":3774,"primaryCompletion":265,"completion":776,"start":3775,"enrollment":3776,"conditions":3777,"interventions":3779},"NCT00719511","Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration",[87],"2008-02",132,[3778],"Allergies",[3763,3780,3781,3782],"Purified allergen dose 2 integrated in a Patch system","Purified allergen dose 3 integrated in a Patch system","Purified allergen integrated in a Patch system",{"trials":3784,"activeCount":97},[],{"trials":3786,"activeCount":97},[],{"trials":3788,"activeCount":97},[],{"intervention":3780,"totalTrials":356,"cells":3790},{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3795,"PHASE3":3801,"PHASE4":3803,"NA":3805},{"trials":3792,"activeCount":97},[],{"trials":3794,"activeCount":97},[],{"trials":3796,"activeCount":97},[3797],{"nctId":3772,"briefTitle":3773,"status":105,"phases":3798,"primaryCompletion":265,"completion":776,"start":3775,"enrollment":3776,"conditions":3799,"interventions":3800},[87],[3778],[3763,3780,3781,3782],{"trials":3802,"activeCount":97},[],{"trials":3804,"activeCount":97},[],{"trials":3806,"activeCount":97},[],{"intervention":3781,"totalTrials":356,"cells":3808},{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3813,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3810,"activeCount":97},[],{"trials":3812,"activeCount":97},[],{"trials":3814,"activeCount":97},[3815],{"nctId":3772,"briefTitle":3773,"status":105,"phases":3816,"primaryCompletion":265,"completion":776,"start":3775,"enrollment":3776,"conditions":3817,"interventions":3818},[87],[3778],[3763,3780,3781,3782],{"trials":3820,"activeCount":97},[],{"trials":3822,"activeCount":97},[],{"trials":3824,"activeCount":97},[],{"intervention":3782,"totalTrials":356,"cells":3826},{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3837,"PHASE4":3839,"NA":3841},{"trials":3828,"activeCount":97},[],{"trials":3830,"activeCount":97},[],{"trials":3832,"activeCount":97},[3833],{"nctId":3772,"briefTitle":3773,"status":105,"phases":3834,"primaryCompletion":265,"completion":776,"start":3775,"enrollment":3776,"conditions":3835,"interventions":3836},[87],[3778],[3763,3780,3781,3782],{"trials":3838,"activeCount":97},[],{"trials":3840,"activeCount":97},[],{"trials":3842,"activeCount":97},[],{"intervention":3844,"totalTrials":356,"cells":3845},"Patupilone",{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3860,"PHASE4":3862,"NA":3864},{"trials":3847,"activeCount":97},[],{"trials":3849,"activeCount":97},[],{"trials":3851,"activeCount":97},[3852],{"nctId":3853,"briefTitle":3854,"status":105,"phases":3855,"primaryCompletion":1340,"completion":1340,"start":3856,"enrollment":337,"conditions":3857,"interventions":3859},"NCT00715013","Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma",[86,87],"2008-07",[3858],"Recurrent Glioblastoma Planned for Reoperation",[3844],{"trials":3861,"activeCount":97},[],{"trials":3863,"activeCount":97},[],{"trials":3865,"activeCount":97},[],{"intervention":3867,"totalTrials":356,"cells":3868},"BCG Vaccine AJVaccines",{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3873,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3870,"activeCount":97},[],{"trials":3872,"activeCount":97},[],{"trials":3874,"activeCount":97},[3875],{"nctId":3876,"briefTitle":3877,"status":105,"phases":3878,"primaryCompletion":3879,"completion":3879,"start":832,"enrollment":2927,"conditions":3880,"interventions":3882},"NCT05004038","BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection:",[87],"2023-09-01",[3881],"HIV-1-infection",[3867],{"trials":3884,"activeCount":97},[],{"trials":3886,"activeCount":97},[],{"trials":3888,"activeCount":97},[],{"intervention":3890,"totalTrials":356,"cells":3891},"drug treatment",{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3906,"PHASE4":3908,"NA":3910},{"trials":3893,"activeCount":97},[],{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":97},[3898],{"nctId":3899,"briefTitle":3900,"status":105,"phases":3901,"completion":3902,"start":2696,"conditions":3903,"interventions":3905},"NCT01038011","Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study",[87],"2006-08",[3904],"Ankylosing Spondylitis",[3890],{"trials":3907,"activeCount":97},[],{"trials":3909,"activeCount":97},[],{"trials":3911,"activeCount":97},[],{"intervention":3913,"totalTrials":356,"cells":3914},"alitretinoin",{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3916,"activeCount":97},[],{"trials":3918,"activeCount":97},[],{"trials":3920,"activeCount":97},[3921],{"nctId":3922,"briefTitle":3923,"status":119,"phases":3924,"primaryCompletion":756,"completion":756,"start":3925,"enrollment":1207,"conditions":3926,"interventions":3928},"NCT01538732","Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin",[87],"2012-03",[3927],"Lichen Planus (LP)",[3913],{"trials":3930,"activeCount":97},[],{"trials":3932,"activeCount":97},[],{"trials":3934,"activeCount":97},[],{"intervention":3936,"totalTrials":356,"cells":3937},"Everolimus",{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3942,"PHASE3":3953,"PHASE4":3955,"NA":3957},{"trials":3939,"activeCount":97},[],{"trials":3941,"activeCount":97},[],{"trials":3943,"activeCount":97},[3944],{"nctId":3945,"briefTitle":3946,"status":105,"phases":3947,"primaryCompletion":3948,"completion":3948,"start":3949,"enrollment":1315,"conditions":3950,"interventions":3952},"NCT01529554","Controlled Level EVERolimus in Acute Coronary Syndromes",[86,87],"2021-11-29","2015-01-08",[3951],"Acute Coronary Syndromes",[3936],{"trials":3954,"activeCount":97},[],{"trials":3956,"activeCount":97},[],{"trials":3958,"activeCount":97},[],{"intervention":3960,"totalTrials":356,"cells":3961},"Prolonged-release Fampridine",{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3966,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3963,"activeCount":97},[],{"trials":3965,"activeCount":97},[],{"trials":3967,"activeCount":97},[3968],{"nctId":3969,"briefTitle":3970,"status":119,"phases":3971,"primaryCompletion":3972,"completion":3972,"start":3925,"enrollment":3973,"conditions":3974,"interventions":3976},"NCT01576354","Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis",[87],"2017-04",70,[3975],"Multiple Sclerosis",[3960],{"trials":3978,"activeCount":97},[],{"trials":3980,"activeCount":97},[],{"trials":3982,"activeCount":97},[],{"intervention":3984,"totalTrials":356,"cells":3985},"Bryophyllum pinnatum, Placebo in form of Lactose",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3999,"PHASE4":4001,"NA":4003},{"trials":3987,"activeCount":97},[],{"trials":3989,"activeCount":97},[],{"trials":3991,"activeCount":97},[3992],{"nctId":3993,"briefTitle":3994,"status":105,"phases":3995,"primaryCompletion":3996,"completion":3996,"start":1340,"enrollment":629,"conditions":3997,"interventions":3998},"NCT01127126","Bryophyllum Versus Placebo for Overactive Bladder",[87],"2012-01",[339],[3984],{"trials":4000,"activeCount":97},[],{"trials":4002,"activeCount":97},[],{"trials":4004,"activeCount":97},[],{"intervention":4006,"totalTrials":356,"cells":4007},"dexamethasone 8 mg bid",{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4012,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4009,"activeCount":97},[],{"trials":4011,"activeCount":97},[],{"trials":4013,"activeCount":97},[4014],{"nctId":4015,"briefTitle":4016,"status":105,"phases":4017,"completion":4018,"start":4019,"enrollment":415,"conditions":4020,"interventions":4022},"NCT00274430","Prevention of High Altitude Pulmonary Edema",[86,87],"2003-09","2003-07",[4021],"High Altitude Pulmonary Edema",[4006,4023],"tadalafil 10mg bid",{"trials":4025,"activeCount":97},[],{"trials":4027,"activeCount":97},[],{"trials":4029,"activeCount":97},[],{"intervention":4023,"totalTrials":356,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4033,"activeCount":97},[],{"trials":4035,"activeCount":97},[],{"trials":4037,"activeCount":97},[4038],{"nctId":4015,"briefTitle":4016,"status":105,"phases":4039,"completion":4018,"start":4019,"enrollment":415,"conditions":4040,"interventions":4041},[86,87],[4021],[4006,4023],{"trials":4043,"activeCount":97},[],{"trials":4045,"activeCount":97},[],{"trials":4047,"activeCount":97},[],{"intervention":725,"totalTrials":356,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":97},[],{"trials":4053,"activeCount":97},[],{"trials":4055,"activeCount":97},[4056],{"nctId":715,"briefTitle":716,"status":717,"phases":4057,"primaryCompletion":719,"completion":719,"start":720,"enrollment":97,"conditions":4058,"interventions":4059},[87],[722],[610,724,725],{"trials":4061,"activeCount":97},[],{"trials":4063,"activeCount":97},[],{"trials":4065,"activeCount":97},[],{"intervention":4067,"totalTrials":356,"cells":4068},"Actemra",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4070,"activeCount":97},[],{"trials":4072,"activeCount":97},[],{"trials":4074,"activeCount":97},[4075],{"nctId":4076,"briefTitle":4077,"status":332,"phases":4078,"primaryCompletion":4079,"completion":4079,"start":4080,"enrollment":1207,"conditions":4081,"interventions":4083},"NCT04652258","Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib\u002F Trametinib +\u002F- Immunotherapy",[87],"2021-10-31","2021-02-01",[4082],"Pyrexia",[4067],{"trials":4085,"activeCount":97},[],{"trials":4087,"activeCount":97},[],{"trials":4089,"activeCount":97},[],{"intervention":4091,"totalTrials":356,"cells":4092},"Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin",{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4106,"PHASE4":4108,"NA":4110},{"trials":4094,"activeCount":97},[],{"trials":4096,"activeCount":97},[],{"trials":4098,"activeCount":97},[4099],{"nctId":4100,"briefTitle":4101,"status":105,"phases":4102,"primaryCompletion":2793,"completion":2793,"start":4103,"enrollment":1646,"conditions":4104,"interventions":4105},"NCT01692704","Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy",[86,87],"2012-04",[3068],[4091],{"trials":4107,"activeCount":97},[],{"trials":4109,"activeCount":97},[],{"trials":4111,"activeCount":97},[],{"intervention":4113,"totalTrials":356,"cells":4114},"OXY111A",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4116,"activeCount":97},[],{"trials":4118,"activeCount":97},[],{"trials":4120,"activeCount":97},[4121],{"nctId":4122,"briefTitle":4123,"status":119,"phases":4124,"primaryCompletion":2429,"completion":2429,"start":4125,"enrollment":4126,"conditions":4127,"interventions":4131},"NCT02528526","Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm",[86,87],"2014-02",69,[1184,4128,4129,4130],"Hepatocellular Cancer","Cholangiocarcinoma","Colorectal Neoplasms",[4113],{"trials":4133,"activeCount":97},[],{"trials":4135,"activeCount":97},[],{"trials":4137,"activeCount":97},[],{"intervention":4139,"totalTrials":356,"cells":4140},"Patch",{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4156,"PHASE4":4158,"NA":4160},{"trials":4142,"activeCount":97},[],{"trials":4144,"activeCount":97},[],{"trials":4146,"activeCount":97},[4147],{"nctId":4148,"briefTitle":4149,"status":105,"phases":4150,"primaryCompletion":108,"completion":108,"start":4151,"enrollment":4152,"conditions":4153,"interventions":4155},"NCT00777374","Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration",[87],"2008-10",97,[4154],"Allergic Rhinoconjunctivitis",[4139],{"trials":4157,"activeCount":97},[],{"trials":4159,"activeCount":97},[],{"trials":4161,"activeCount":97},[],{"intervention":4163,"totalTrials":356,"cells":4164},"Dolutegravir",{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4169,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4166,"activeCount":97},[],{"trials":4168,"activeCount":97},[],{"trials":4170,"activeCount":97},[4171],{"nctId":4172,"briefTitle":4173,"status":119,"phases":4174,"primaryCompletion":4175,"completion":4176,"start":4177,"enrollment":4178,"conditions":4179,"interventions":4183},"NCT02551523","Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection",[87],"2018-10","2021-02","2016-11",101,[4180,4163,4181,4182],"Monotherapy","Primary HIV Infection","Treatment Efficacy",[4163,4184],"Standard of care combinational antiretroviral therapy",{"trials":4186,"activeCount":97},[],{"trials":4188,"activeCount":97},[],{"trials":4190,"activeCount":97},[],{"intervention":4184,"totalTrials":356,"cells":4192},{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4203,"PHASE4":4205,"NA":4207},{"trials":4194,"activeCount":97},[],{"trials":4196,"activeCount":97},[],{"trials":4198,"activeCount":97},[4199],{"nctId":4172,"briefTitle":4173,"status":119,"phases":4200,"primaryCompletion":4175,"completion":4176,"start":4177,"enrollment":4178,"conditions":4201,"interventions":4202},[87],[4180,4163,4181,4182],[4163,4184],{"trials":4204,"activeCount":97},[],{"trials":4206,"activeCount":97},[],{"trials":4208,"activeCount":97},[],{"intervention":4210,"totalTrials":356,"cells":4211},"Lapatinib",{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4225,"PHASE4":4227,"NA":4229},{"trials":4213,"activeCount":97},[],{"trials":4215,"activeCount":97},[],{"trials":4217,"activeCount":97},[4218],{"nctId":4219,"briefTitle":4220,"status":332,"phases":4221,"primaryCompletion":1551,"completion":1551,"start":2953,"enrollment":36,"conditions":4222,"interventions":4224},"NCT01666431","Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment",[87],[4223],"Squamous Cell Carcinoma",[4210],{"trials":4226,"activeCount":97},[],{"trials":4228,"activeCount":97},[],{"trials":4230,"activeCount":97},[],{"intervention":4232,"totalTrials":356,"cells":4233},"Pollen",{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4246,"PHASE3":4248,"PHASE4":4250,"NA":4252},{"trials":4235,"activeCount":97},[],{"trials":4237,"activeCount":97},[4238],{"nctId":4239,"briefTitle":4240,"status":105,"phases":4241,"completion":1131,"start":4242,"enrollment":4243,"conditions":4244,"interventions":4245},"NCT00457444","Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration",[86],"2005-12",35,[2915],[4232],{"trials":4247,"activeCount":97},[],{"trials":4249,"activeCount":97},[],{"trials":4251,"activeCount":97},[],{"trials":4253,"activeCount":97},[],{"intervention":4255,"totalTrials":356,"cells":4256},"Baminercept",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4269,"PHASE3":4271,"PHASE4":4273,"NA":4275},{"trials":4258,"activeCount":97},[],{"trials":4260,"activeCount":97},[4261],{"nctId":4262,"briefTitle":4263,"status":119,"phases":4264,"completion":1459,"start":4265,"conditions":4266,"interventions":4268},"NCT01164384","A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.",[86],"2010-10",[4267],"Chronic HCV Hepatitis C",[4255],{"trials":4270,"activeCount":97},[],{"trials":4272,"activeCount":97},[],{"trials":4274,"activeCount":97},[],{"trials":4276,"activeCount":97},[],{"intervention":4278,"totalTrials":356,"cells":4279},"Syntocinon (Oxytocin) nasal spray",{"EARLY_PHASE1":4280,"PHASE1":4282,"PHASE2":4292,"PHASE3":4294,"PHASE4":4296,"NA":4298},{"trials":4281,"activeCount":97},[],{"trials":4283,"activeCount":97},[4284],{"nctId":4285,"briefTitle":4286,"status":105,"phases":4287,"primaryCompletion":1206,"completion":1206,"start":4288,"enrollment":4289,"conditions":4290,"interventions":4291},"NCT01594775","Oxytocin, Couple Interaction and Wound Healing",[86],"2011-10",160,[1700],[4278],{"trials":4293,"activeCount":97},[],{"trials":4295,"activeCount":97},[],{"trials":4297,"activeCount":97},[],{"trials":4299,"activeCount":97},[],{"intervention":4301,"totalTrials":356,"cells":4302},"Simvastatin",{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4315,"PHASE3":4317,"PHASE4":4319,"NA":4321},{"trials":4304,"activeCount":97},[],{"trials":4306,"activeCount":97},[4307],{"nctId":4308,"briefTitle":4309,"status":332,"phases":4310,"primaryCompletion":2073,"completion":4125,"start":4311,"enrollment":1646,"conditions":4312,"interventions":4314},"NCT01642862","Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration",[86],"2012-07",[4313],"Celiac Disease",[4301],{"trials":4316,"activeCount":97},[],{"trials":4318,"activeCount":97},[],{"trials":4320,"activeCount":97},[],{"trials":4322,"activeCount":97},[],{"intervention":4324,"totalTrials":356,"cells":4325},"Photodynamic therapy with Gliolan",{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4338,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4327,"activeCount":97},[],{"trials":4329,"activeCount":97},[4330],{"nctId":4331,"briefTitle":4332,"status":119,"phases":4333,"primaryCompletion":107,"completion":107,"start":4334,"enrollment":4335,"conditions":4336,"interventions":4337},"NCT01697670","Photodynamic Therapy for Ulcerative Colitis",[86],"2012-09",7,[3024],[4324],{"trials":4339,"activeCount":97},[],{"trials":4341,"activeCount":97},[],{"trials":4343,"activeCount":97},[],{"trials":4345,"activeCount":97},[],{"intervention":4347,"totalTrials":356,"cells":4348},"Tolcapone",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4360,"PHASE3":4362,"PHASE4":4364,"NA":4366},{"trials":4350,"activeCount":97},[],{"trials":4352,"activeCount":97},[4353],{"nctId":4354,"briefTitle":4355,"status":105,"phases":4356,"primaryCompletion":3517,"completion":3517,"start":4357,"enrollment":415,"conditions":4358,"interventions":4359},"NCT02080715","Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance",[86],"2013-06",[15],[4347],{"trials":4361,"activeCount":97},[],{"trials":4363,"activeCount":97},[],{"trials":4365,"activeCount":97},[],{"trials":4367,"activeCount":97},[],{"intervention":4369,"totalTrials":356,"cells":4370},"Azathioprine \u002F Allopurinol",{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4383,"PHASE3":4385,"PHASE4":4387,"NA":4389},{"trials":4372,"activeCount":97},[],{"trials":4374,"activeCount":97},[4375],{"nctId":4376,"briefTitle":4377,"status":105,"phases":4378,"primaryCompletion":1721,"completion":1721,"start":440,"enrollment":4379,"conditions":4380,"interventions":4382},"NCT00849368","Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients",[86],6,[4381],"Inflammatory Bowel Disease",[4369],{"trials":4384,"activeCount":97},[],{"trials":4386,"activeCount":97},[],{"trials":4388,"activeCount":97},[],{"trials":4390,"activeCount":97},[],{"intervention":4392,"totalTrials":356,"cells":4393},"[18F]-GP1",{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4407,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4395,"activeCount":97},[],{"trials":4397,"activeCount":97},[4398],{"nctId":4399,"briefTitle":4400,"status":332,"phases":4401,"primaryCompletion":4402,"completion":4402,"start":1076,"enrollment":1011,"conditions":4403,"interventions":4406},"NCT02469376","Evaluation of a New Imagingtechnologie for Thrombosis",[86],"2016-12-01",[4404,4405],"Abdominal Aortic Aneurysm","Deep Vein Thrombosis",[4392],{"trials":4408,"activeCount":97},[],{"trials":4410,"activeCount":97},[],{"trials":4412,"activeCount":97},[],{"trials":4414,"activeCount":97},[],{"intervention":4416,"totalTrials":356,"cells":4417},"Methylnaltrexone",{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4419,"activeCount":97},[],{"trials":4421,"activeCount":97},[4422],{"nctId":4423,"briefTitle":4424,"status":105,"phases":4425,"primaryCompletion":1312,"completion":1312,"start":4125,"enrollment":337,"conditions":4426,"interventions":4428},"NCT01889290","Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients",[86],[4427],"Opioid Use, Unspecified With Other Opioid-induced Disorder",[4416],{"trials":4430,"activeCount":97},[],{"trials":4432,"activeCount":97},[],{"trials":4434,"activeCount":97},[],{"trials":4436,"activeCount":97},[],{"intervention":4438,"totalTrials":356,"cells":4439},"IVN201",{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4451,"PHASE3":4453,"PHASE4":4455,"NA":4457},{"trials":4441,"activeCount":97},[],{"trials":4443,"activeCount":97},[4444],{"nctId":4445,"briefTitle":4446,"status":105,"phases":4447,"primaryCompletion":1055,"completion":1055,"start":3856,"enrollment":1207,"conditions":4448,"interventions":4450},"NCT00718679","Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial",[86],[4449],"Allergy to Cat Dander",[4438],{"trials":4452,"activeCount":97},[],{"trials":4454,"activeCount":97},[],{"trials":4456,"activeCount":97},[],{"trials":4458,"activeCount":97},[],{"intervention":2988,"totalTrials":356,"cells":4460},{"EARLY_PHASE1":4461,"PHASE1":4463,"PHASE2":4469,"PHASE3":4471,"PHASE4":4473,"NA":4475},{"trials":4462,"activeCount":97},[],{"trials":4464,"activeCount":97},[4465],{"nctId":2980,"briefTitle":2981,"status":105,"phases":4466,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":2985,"conditions":4467,"interventions":4468},[86],[15],[2973,2988,2989],{"trials":4470,"activeCount":97},[],{"trials":4472,"activeCount":97},[],{"trials":4474,"activeCount":97},[],{"trials":4476,"activeCount":97},[],{"intervention":4478,"totalTrials":356,"cells":4479},"denovoDerm",{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4497,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4481,"activeCount":97},[],{"trials":4483,"activeCount":97},[4484],{"nctId":4485,"briefTitle":4486,"status":105,"phases":4487,"primaryCompletion":4488,"completion":4488,"start":336,"enrollment":1646,"conditions":4489,"interventions":4495},"NCT02145130","Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects",[86],"2021-03",[1078,4490,4491,4492,4493,4494],"Soft Tissue Injury","Skin Necrosis","Scars","Congenital Giant Nevus","Skin Tumors",[4478,4496],"denovoSkin",{"trials":4498,"activeCount":97},[],{"trials":4500,"activeCount":97},[],{"trials":4502,"activeCount":97},[],{"trials":4504,"activeCount":97},[],{"intervention":4496,"totalTrials":356,"cells":4506},{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4515,"PHASE3":4517,"PHASE4":4519,"NA":4521},{"trials":4508,"activeCount":97},[],{"trials":4510,"activeCount":97},[4511],{"nctId":4485,"briefTitle":4486,"status":105,"phases":4512,"primaryCompletion":4488,"completion":4488,"start":336,"enrollment":1646,"conditions":4513,"interventions":4514},[86],[1078,4490,4491,4492,4493,4494],[4478,4496],{"trials":4516,"activeCount":97},[],{"trials":4518,"activeCount":97},[],{"trials":4520,"activeCount":97},[],{"trials":4522,"activeCount":97},[],{"intervention":4524,"totalTrials":356,"cells":4525},"Anakinra",{"EARLY_PHASE1":4526,"PHASE1":4528,"PHASE2":4538,"PHASE3":4540,"PHASE4":4542,"NA":4544},{"trials":4527,"activeCount":97},[],{"trials":4529,"activeCount":97},[4530],{"nctId":4531,"briefTitle":4532,"status":105,"phases":4533,"primaryCompletion":1672,"start":4534,"enrollment":1207,"conditions":4535,"interventions":4537},"NCT01810549","Role of Interleukin-1 in Postprandial Fatigue - The Cheesecake Study",[86],"2013-03",[4536],"Postprandial Fatigue",[4524],{"trials":4539,"activeCount":97},[],{"trials":4541,"activeCount":97},[],{"trials":4543,"activeCount":97},[],{"trials":4545,"activeCount":97},[],{"intervention":4547,"totalTrials":356,"cells":4548},"25(OH)D",{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4561,"PHASE3":4563,"PHASE4":4565,"NA":4567},{"trials":4550,"activeCount":97},[],{"trials":4552,"activeCount":97},[4553],{"nctId":4554,"briefTitle":4555,"status":105,"phases":4556,"primaryCompletion":1339,"completion":4557,"start":4558,"enrollment":4243,"conditions":4559,"interventions":4560},"NCT00718276","Pharmacokinetic Study: Effect of 25(OH)D and Vitamin D3 on Serum 25(OH)D",[86],"2008-09","2008-03",[15],[4547],{"trials":4562,"activeCount":97},[],{"trials":4564,"activeCount":97},[],{"trials":4566,"activeCount":97},[],{"trials":4568,"activeCount":97},[],{"intervention":4570,"totalTrials":356,"cells":4571},"Chloroquine",{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4583,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4573,"activeCount":97},[],{"trials":4575,"activeCount":97},[4576],{"nctId":4577,"briefTitle":4578,"status":105,"phases":4579,"primaryCompletion":1100,"completion":1100,"start":4311,"enrollment":337,"conditions":4580,"interventions":4581},"NCT01777477","Adjuvant Effect of Chloroquine on Gemcitabine",[86],[2822],[4570,4582],"Gemcitabine",{"trials":4584,"activeCount":97},[],{"trials":4586,"activeCount":97},[],{"trials":4588,"activeCount":97},[],{"trials":4590,"activeCount":97},[],{"intervention":4582,"totalTrials":356,"cells":4592},{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4601,"PHASE3":4603,"PHASE4":4605,"NA":4607},{"trials":4594,"activeCount":97},[],{"trials":4596,"activeCount":97},[4597],{"nctId":4577,"briefTitle":4578,"status":105,"phases":4598,"primaryCompletion":1100,"completion":1100,"start":4311,"enrollment":337,"conditions":4599,"interventions":4600},[86],[2822],[4570,4582],{"trials":4602,"activeCount":97},[],{"trials":4604,"activeCount":97},[],{"trials":4606,"activeCount":97},[],{"trials":4608,"activeCount":97},[],{"intervention":4610,"totalTrials":356,"cells":4611},"PF-06412562",{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4625,"PHASE3":4627,"PHASE4":4629,"NA":4631},{"trials":4613,"activeCount":97},[],{"trials":4615,"activeCount":97},[4616],{"nctId":4617,"briefTitle":4618,"status":105,"phases":4619,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":451,"conditions":4622,"interventions":4624},"NCT03181841","Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals",[86],"2017-12-20","2017-05-08",[4623],"Decision Making",[4610],{"trials":4626,"activeCount":97},[],{"trials":4628,"activeCount":97},[],{"trials":4630,"activeCount":97},[],{"trials":4632,"activeCount":97},[],{"intervention":4634,"totalTrials":356,"cells":4635},"Convalescent plasma",{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4649,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4637,"activeCount":97},[],{"trials":4639,"activeCount":97},[4640],{"nctId":4641,"briefTitle":4642,"status":105,"phases":4643,"primaryCompletion":4644,"completion":4645,"start":4646,"enrollment":415,"conditions":4647,"interventions":4648},"NCT04869072","Convalescent Plasma Therapy - Zurich Protocol",[86],"2020-11-30","2021-03-30","2020-04-29",[2673],[4634],{"trials":4650,"activeCount":97},[],{"trials":4652,"activeCount":97},[],{"trials":4654,"activeCount":97},[],{"trials":4656,"activeCount":97},[],{"intervention":4658,"totalTrials":356,"cells":4659},"Talimogene Laherparepvec",{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4677,"PHASE3":4679,"PHASE4":4681,"NA":4683},{"trials":4661,"activeCount":97},[],{"trials":4663,"activeCount":97},[4664],{"nctId":4665,"briefTitle":4666,"status":105,"phases":4667,"primaryCompletion":4668,"completion":4669,"start":4670,"enrollment":11,"conditions":4671,"interventions":4676},"NCT03458117","T-VEC in Non-melanoma Skin Cancer",[86],"2022-02-04","2022-03-15","2018-04-19",[4672,4673,4223,4674,4675],"Non-melanoma Skin Cancer","Basal Cell Carcinoma","Cutaneous Lymphoma","Merkel Cell Carcinoma",[4658],{"trials":4678,"activeCount":97},[],{"trials":4680,"activeCount":97},[],{"trials":4682,"activeCount":97},[],{"trials":4684,"activeCount":97},[],{"intervention":4686,"totalTrials":356,"cells":4687},"200 mg levodopa\u002F50 mg benserazide",{"EARLY_PHASE1":4688,"PHASE1":4701,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4689,"activeCount":97},[4690],{"nctId":4691,"briefTitle":4692,"status":105,"phases":4693,"primaryCompletion":4694,"completion":4694,"start":4695,"enrollment":4696,"conditions":4697,"interventions":4699},"NCT03333369","Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission",[85],"2015-08-13","2014-05-15",65,[15,4698],"Schizotypal Personality",[4686,4700],"Dextrose",{"trials":4702,"activeCount":97},[],{"trials":4704,"activeCount":97},[],{"trials":4706,"activeCount":97},[],{"trials":4708,"activeCount":97},[],{"trials":4710,"activeCount":97},[],{"intervention":4700,"totalTrials":356,"cells":4712},{"EARLY_PHASE1":4713,"PHASE1":4719,"PHASE2":4721,"PHASE3":4723,"PHASE4":4725,"NA":4727},{"trials":4714,"activeCount":97},[4715],{"nctId":4691,"briefTitle":4692,"status":105,"phases":4716,"primaryCompletion":4694,"completion":4694,"start":4695,"enrollment":4696,"conditions":4717,"interventions":4718},[85],[15,4698],[4686,4700],{"trials":4720,"activeCount":97},[],{"trials":4722,"activeCount":97},[],{"trials":4724,"activeCount":97},[],{"trials":4726,"activeCount":97},[],{"trials":4728,"activeCount":97},[],{"intervention":4730,"totalTrials":356,"cells":4731},"Photodynamic Therapy",{"EARLY_PHASE1":4732,"PHASE1":4745,"PHASE2":4747,"PHASE3":4749,"PHASE4":4751,"NA":4753},{"trials":4733,"activeCount":97},[4734],{"nctId":4735,"briefTitle":4736,"status":119,"phases":4737,"primaryCompletion":3879,"completion":122,"start":4738,"enrollment":1207,"conditions":4739,"interventions":4744},"NCT05676801","Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III)",[85],"2023-02-04",[4740,4741,4742,4743],"Prosthesis and Implants","Surgical Site Infection","Prosthetic Joint Infection","Postoperative Wound Infection Deep Incisional Surgical Site",[4730],{"trials":4746,"activeCount":97},[],{"trials":4748,"activeCount":97},[],{"trials":4750,"activeCount":97},[],{"trials":4752,"activeCount":97},[],{"trials":4754,"activeCount":97},[],{"intervention":4756,"totalTrials":356,"cells":4757},"Adoptive Transfer of re-directed T cells",{"EARLY_PHASE1":4758,"PHASE1":4769,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4759,"activeCount":97},[4760],{"nctId":4761,"briefTitle":4762,"status":105,"phases":4763,"primaryCompletion":4764,"completion":4765,"start":4766,"enrollment":1011,"conditions":4767,"interventions":4768},"NCT01722149","Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma",[85],"2019-03-22","2019-07-18","2015-02-19",[3093],[4756],{"trials":4770,"activeCount":97},[],{"trials":4772,"activeCount":97},[],{"trials":4774,"activeCount":97},[],{"trials":4776,"activeCount":97},[],{"trials":4778,"activeCount":97},[],{"intervention":724,"totalTrials":361,"cells":4780},{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4785,"PHASE3":4791,"PHASE4":4793,"NA":4803},{"trials":4782,"activeCount":97},[],{"trials":4784,"activeCount":97},[],{"trials":4786,"activeCount":97},[4787],{"nctId":715,"briefTitle":716,"status":717,"phases":4788,"primaryCompletion":719,"completion":719,"start":720,"enrollment":97,"conditions":4789,"interventions":4790},[87],[722],[610,724,725],{"trials":4792,"activeCount":97},[],{"trials":4794,"activeCount":97},[4795,4799],{"nctId":1165,"briefTitle":1166,"status":105,"phases":4796,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":1170,"conditions":4797,"interventions":4798},[89],[1172],[1152,724],{"nctId":752,"briefTitle":753,"status":105,"phases":4800,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":4801,"interventions":4802},[89],[759],[610,724],{"trials":4804,"activeCount":97},[4805,4809],{"nctId":773,"briefTitle":774,"status":105,"phases":4806,"primaryCompletion":265,"completion":776,"start":777,"enrollment":451,"conditions":4807,"interventions":4808},[90],[779],[610,724],{"nctId":793,"briefTitle":794,"status":105,"phases":4810,"primaryCompletion":796,"completion":797,"start":440,"enrollment":692,"conditions":4811,"interventions":4812},[90],[799],[724,610],{"intervention":4814,"totalTrials":1011,"cells":4815},"Bevacizumab",{"EARLY_PHASE1":4816,"PHASE1":4818,"PHASE2":4820,"PHASE3":4828,"PHASE4":4830,"NA":4832},{"trials":4817,"activeCount":97},[],{"trials":4819,"activeCount":97},[],{"trials":4821,"activeCount":97},[4822],{"nctId":4823,"briefTitle":4824,"status":105,"phases":4825,"primaryCompletion":1550,"completion":1313,"start":4288,"enrollment":1483,"conditions":4826,"interventions":4827},"NCT01443676","Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma",[87],[444],[4814],{"trials":4829,"activeCount":97},[],{"trials":4831,"activeCount":97},[],{"trials":4833,"activeCount":97},[4834,4844,4853],{"nctId":4835,"briefTitle":4836,"status":105,"phases":4837,"primaryCompletion":4838,"completion":2819,"start":1871,"enrollment":4839,"conditions":4840,"interventions":4842},"NCT00875147","Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases",[],"2009-08",163,[4841],"Colorectal Liver Metastases",[4843],"bevacizumab",{"nctId":4845,"briefTitle":4846,"status":105,"phases":4847,"primaryCompletion":107,"completion":1206,"start":3856,"enrollment":4848,"conditions":4849,"interventions":4851},"NCT00727753","VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)",[],54,[4850],"Macular Degeneration",[4852,4814],"Ranibizumab",{"nctId":4854,"briefTitle":4855,"status":332,"phases":4856,"primaryCompletion":796,"completion":796,"start":1130,"enrollment":442,"conditions":4857,"interventions":4859},"NCT01046279","Hypertension Monitoring in Glioma Patients Treated With Bevacizumab",[],[4858],"Glioma Patients",[4814],{"intervention":2989,"totalTrials":1043,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4870,"PHASE3":4872,"PHASE4":4874,"NA":4876},{"trials":4863,"activeCount":97},[],{"trials":4865,"activeCount":97},[4866],{"nctId":2980,"briefTitle":2981,"status":105,"phases":4867,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":2985,"conditions":4868,"interventions":4869},[86],[15],[2973,2988,2989],{"trials":4871,"activeCount":97},[],{"trials":4873,"activeCount":97},[],{"trials":4875,"activeCount":97},[],{"trials":4877,"activeCount":97},[4878,4888],{"nctId":4879,"briefTitle":4880,"status":105,"phases":4881,"primaryCompletion":4882,"completion":4882,"start":4883,"enrollment":4289,"conditions":4884,"interventions":4885},"NCT04384562","Studying the Role of Brain Molecules for Decision Making",[90],"2021-12-13","2020-12-17",[4623,15],[2989,4886,4887],"Reboxetine","Nicotine gum",{"nctId":4889,"briefTitle":4890,"status":105,"phases":4891,"primaryCompletion":4892,"completion":4892,"start":4893,"enrollment":451,"conditions":4894,"interventions":4895},"NCT04371146","The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making",[90],"2020-02-13","2019-07-03",[15],[2989,4886,3684],{"intervention":4897,"totalTrials":315,"cells":4898},"Exposure to golimumab",{"EARLY_PHASE1":4899,"PHASE1":4901,"PHASE2":4903,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4900,"activeCount":97},[],{"trials":4902,"activeCount":97},[],{"trials":4904,"activeCount":97},[],{"trials":4906,"activeCount":97},[],{"trials":4908,"activeCount":97},[],{"trials":4910,"activeCount":97},[4911,4920],{"nctId":4912,"briefTitle":4913,"status":105,"phases":4914,"primaryCompletion":134,"completion":134,"start":4915,"enrollment":4916,"conditions":4917,"interventions":4919},"NCT05405465","Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland",[],"2018-01-01",103,[3024,4918],"Flare Up, Symptom",[4897],{"nctId":4921,"briefTitle":4922,"status":119,"phases":4923,"primaryCompletion":4924,"completion":4924,"start":4915,"enrollment":124,"conditions":4925,"interventions":4926},"NCT03394586","Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab",[],"2018-12-31",[3024,4918],[4897],{"intervention":4928,"totalTrials":315,"cells":4929},"Sertindole",{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4936,"PHASE4":4938,"NA":4940},{"trials":4931,"activeCount":97},[],{"trials":4933,"activeCount":97},[],{"trials":4935,"activeCount":97},[],{"trials":4937,"activeCount":97},[],{"trials":4939,"activeCount":97},[],{"trials":4941,"activeCount":97},[4942,4949],{"nctId":4943,"briefTitle":4944,"status":105,"phases":4945,"primaryCompletion":4151,"completion":4946,"start":441,"enrollment":415,"conditions":4947,"interventions":4948},"NCT00612079","The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers",[90],"2008-11",[15],[4928],{"nctId":4950,"briefTitle":4951,"status":332,"phases":4952,"primaryCompletion":796,"completion":796,"start":3775,"enrollment":30,"conditions":4953,"interventions":4955},"NCT00629252","The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients",[90],[4954],"Schizophrenia",[4928,4956],"Risperidone",{"intervention":4886,"totalTrials":315,"cells":4958},{"EARLY_PHASE1":4959,"PHASE1":4961,"PHASE2":4963,"PHASE3":4965,"PHASE4":4967,"NA":4969},{"trials":4960,"activeCount":97},[],{"trials":4962,"activeCount":97},[],{"trials":4964,"activeCount":97},[],{"trials":4966,"activeCount":97},[],{"trials":4968,"activeCount":97},[],{"trials":4970,"activeCount":97},[4971,4975],{"nctId":4879,"briefTitle":4880,"status":105,"phases":4972,"primaryCompletion":4882,"completion":4882,"start":4883,"enrollment":4289,"conditions":4973,"interventions":4974},[90],[4623,15],[2989,4886,4887],{"nctId":4889,"briefTitle":4890,"status":105,"phases":4976,"primaryCompletion":4892,"completion":4892,"start":4893,"enrollment":451,"conditions":4977,"interventions":4978},[90],[15],[2989,4886,3684],{"intervention":3684,"totalTrials":315,"cells":4980},{"EARLY_PHASE1":4981,"PHASE1":4983,"PHASE2":4985,"PHASE3":4991,"PHASE4":4993,"NA":4995},{"trials":4982,"activeCount":97},[],{"trials":4984,"activeCount":97},[],{"trials":4986,"activeCount":97},[4987],{"nctId":3675,"briefTitle":3676,"status":105,"phases":4988,"primaryCompletion":3678,"completion":3678,"start":3679,"enrollment":3680,"conditions":4989,"interventions":4990},[87],[3682],[3666,3684],{"trials":4992,"activeCount":97},[],{"trials":4994,"activeCount":97},[],{"trials":4996,"activeCount":97},[4997],{"nctId":4889,"briefTitle":4890,"status":105,"phases":4998,"primaryCompletion":4892,"completion":4892,"start":4893,"enrollment":451,"conditions":4999,"interventions":5000},[90],[15],[2989,4886,3684],{"intervention":5002,"totalTrials":315,"cells":5003},"Cortisol",{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5010,"PHASE4":5012,"NA":5014},{"trials":5005,"activeCount":97},[],{"trials":5007,"activeCount":97},[],{"trials":5009,"activeCount":97},[],{"trials":5011,"activeCount":97},[],{"trials":5013,"activeCount":97},[],{"trials":5015,"activeCount":97},[5016,5023],{"nctId":5017,"briefTitle":5018,"status":105,"phases":5019,"primaryCompletion":2819,"completion":2819,"start":1341,"enrollment":442,"conditions":5020,"interventions":5022},"NCT00451750","Cortisol in the Treatment of Phobias",[90],[5021],"Phobia",[5002],{"nctId":5024,"briefTitle":5025,"status":332,"phases":5026,"primaryCompletion":776,"completion":776,"start":2120,"enrollment":1207,"conditions":5027,"interventions":5029},"NCT00362661","Low-dose Cortisol in Chronic Posttraumatic Stress Disorder",[90],[5028],"Posttraumatic Stress Disorder",[5002],{"intervention":5031,"totalTrials":315,"cells":5032},"Psilocybine",{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5034,"activeCount":97},[],{"trials":5036,"activeCount":97},[],{"trials":5038,"activeCount":97},[5039],{"nctId":5040,"briefTitle":5041,"status":105,"phases":5042,"primaryCompletion":5043,"completion":2669,"start":5044,"enrollment":5045,"conditions":5046,"interventions":5048},"NCT03715127","Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept",[87],"2021-10-12","2019-03-11",55,[5047],"Depressive Disorder, Major",[5049],"Psilocybine oral",{"trials":5051,"activeCount":97},[],{"trials":5053,"activeCount":97},[],{"trials":5055,"activeCount":97},[5056],{"nctId":5057,"briefTitle":5058,"status":105,"phases":5059,"primaryCompletion":4924,"completion":4924,"start":5060,"enrollment":5061,"conditions":5062,"interventions":5063},"NCT03736980","Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self",[90],"2013-10-01",140,[15],[5031],{"intervention":5065,"totalTrials":356,"cells":5066},"Raltegravir",{"EARLY_PHASE1":5067,"PHASE1":5069,"PHASE2":5071,"PHASE3":5073,"PHASE4":5075,"NA":5077},{"trials":5068,"activeCount":97},[],{"trials":5070,"activeCount":97},[],{"trials":5072,"activeCount":97},[],{"trials":5074,"activeCount":97},[],{"trials":5076,"activeCount":97},[],{"trials":5078,"activeCount":97},[5079],{"nctId":5080,"briefTitle":5081,"status":105,"phases":5082,"primaryCompletion":3655,"completion":1169,"start":5083,"enrollment":2865,"conditions":5084,"interventions":5086},"NCT00904644","Raltegravir in the Swiss HIV Cohort Study",[],"2008-04",[5085],"HIV Infection",[5065],{"intervention":5088,"totalTrials":356,"cells":5089},"Levosimendan",{"EARLY_PHASE1":5090,"PHASE1":5092,"PHASE2":5094,"PHASE3":5096,"PHASE4":5098,"NA":5100},{"trials":5091,"activeCount":97},[],{"trials":5093,"activeCount":97},[],{"trials":5095,"activeCount":97},[],{"trials":5097,"activeCount":97},[],{"trials":5099,"activeCount":97},[],{"trials":5101,"activeCount":97},[5102],{"nctId":5103,"briefTitle":5104,"status":105,"phases":5105,"primaryCompletion":5106,"completion":5106,"start":5107,"enrollment":5108,"conditions":5109,"interventions":5113},"NCT04917497","Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock",[],"2014-04-30","2011-06-30",43,[5110,5111,5112],"Cardiogenic Shock","Cardiorenal Syndrome","Acute Kidney Failure",[5088],{"intervention":4852,"totalTrials":356,"cells":5115},{"EARLY_PHASE1":5116,"PHASE1":5118,"PHASE2":5120,"PHASE3":5122,"PHASE4":5124,"NA":5126},{"trials":5117,"activeCount":97},[],{"trials":5119,"activeCount":97},[],{"trials":5121,"activeCount":97},[],{"trials":5123,"activeCount":97},[],{"trials":5125,"activeCount":97},[],{"trials":5127,"activeCount":97},[5128],{"nctId":4845,"briefTitle":4846,"status":105,"phases":5129,"primaryCompletion":107,"completion":1206,"start":3856,"enrollment":4848,"conditions":5130,"interventions":5131},[],[4850],[4852,4814],{"intervention":5133,"totalTrials":356,"cells":5134},"application of lactulose",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5141,"PHASE4":5143,"NA":5145},{"trials":5136,"activeCount":97},[],{"trials":5138,"activeCount":97},[],{"trials":5140,"activeCount":97},[],{"trials":5142,"activeCount":97},[],{"trials":5144,"activeCount":97},[],{"trials":5146,"activeCount":97},[5147],{"nctId":5148,"briefTitle":5149,"status":105,"phases":5150,"primaryCompletion":5151,"completion":5151,"start":5152,"enrollment":406,"conditions":5153,"interventions":5155},"NCT02397512","Elucidating the Influence of Lactulose Intake on the Gut Microbiota Composition",[90],"2015-10-01","2015-02",[5154],"Changes in Gut Microbiota Composition After Lactulose Exposure",[5133],{"intervention":4956,"totalTrials":356,"cells":5157},{"EARLY_PHASE1":5158,"PHASE1":5160,"PHASE2":5162,"PHASE3":5164,"PHASE4":5166,"NA":5168},{"trials":5159,"activeCount":97},[],{"trials":5161,"activeCount":97},[],{"trials":5163,"activeCount":97},[],{"trials":5165,"activeCount":97},[],{"trials":5167,"activeCount":97},[],{"trials":5169,"activeCount":97},[5170],{"nctId":4950,"briefTitle":4951,"status":332,"phases":5171,"primaryCompletion":796,"completion":796,"start":3775,"enrollment":30,"conditions":5172,"interventions":5173},[90],[4954],[4928,4956],{"intervention":5175,"totalTrials":356,"cells":5176},"hematopoietic stem cell",{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5183,"PHASE4":5185,"NA":5187},{"trials":5178,"activeCount":97},[],{"trials":5180,"activeCount":97},[],{"trials":5182,"activeCount":97},[],{"trials":5184,"activeCount":97},[],{"trials":5186,"activeCount":97},[],{"trials":5188,"activeCount":97},[5189],{"nctId":5190,"briefTitle":5191,"status":119,"phases":5192,"primaryCompletion":5193,"completion":46,"start":1108,"enrollment":25,"conditions":5194,"interventions":5196},"NCT02176434","Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease",[90],"2024-12",[5195],"End Stage Renal Disease",[5175],{"intervention":5198,"totalTrials":356,"cells":5199},"\"Mutaflor Suspension\"",{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5208,"NA":5210},{"trials":5201,"activeCount":97},[],{"trials":5203,"activeCount":97},[],{"trials":5205,"activeCount":97},[],{"trials":5207,"activeCount":97},[],{"trials":5209,"activeCount":97},[],{"trials":5211,"activeCount":97},[5212],{"nctId":5213,"briefTitle":5214,"status":119,"phases":5215,"primaryCompletion":5216,"completion":5216,"start":5217,"enrollment":442,"conditions":5218,"interventions":5220},"NCT03800147","Effects of Nutritional Fat on the Growth of Intestinal E. Coli",[90],"2019-09-24","2019-01-24",[5219],"Escherichia Coli Infections",[5198],{"intervention":5222,"totalTrials":356,"cells":5223},"Bryophyllum pinnatum 50 %, tablets into",{"EARLY_PHASE1":5224,"PHASE1":5226,"PHASE2":5228,"PHASE3":5230,"PHASE4":5232,"NA":5234},{"trials":5225,"activeCount":97},[],{"trials":5227,"activeCount":97},[],{"trials":5229,"activeCount":97},[],{"trials":5231,"activeCount":97},[],{"trials":5233,"activeCount":97},[],{"trials":5235,"activeCount":97},[5236],{"nctId":5237,"briefTitle":5238,"status":105,"phases":5239,"primaryCompletion":5240,"completion":5241,"start":4915,"enrollment":394,"conditions":5242,"interventions":5245},"NCT04480658","Effectiveness of Bryophyllum in Nocturia-Therapy",[90],"2021-02-18","2022-01-14",[5243,5244],"Nocturia","Sleep Disorder",[5222],{"intervention":5247,"totalTrials":356,"cells":5248},"Rufinamid",{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5255,"PHASE4":5257,"NA":5259},{"trials":5250,"activeCount":97},[],{"trials":5252,"activeCount":97},[],{"trials":5254,"activeCount":97},[],{"trials":5256,"activeCount":97},[],{"trials":5258,"activeCount":97},[],{"trials":5260,"activeCount":97},[5261],{"nctId":5262,"briefTitle":5263,"status":105,"phases":5264,"primaryCompletion":1252,"completion":1252,"start":4265,"enrollment":19,"conditions":5265,"interventions":5267},"NCT01212458","Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study",[],[5266],"Healthy Subjects",[5247],{"intervention":4887,"totalTrials":356,"cells":5269},{"EARLY_PHASE1":5270,"PHASE1":5272,"PHASE2":5274,"PHASE3":5276,"PHASE4":5278,"NA":5280},{"trials":5271,"activeCount":97},[],{"trials":5273,"activeCount":97},[],{"trials":5275,"activeCount":97},[],{"trials":5277,"activeCount":97},[],{"trials":5279,"activeCount":97},[],{"trials":5281,"activeCount":97},[5282],{"nctId":4879,"briefTitle":4880,"status":105,"phases":5283,"primaryCompletion":4882,"completion":4882,"start":4883,"enrollment":4289,"conditions":5284,"interventions":5285},[90],[4623,15],[2989,4886,4887],{"intervention":5287,"totalTrials":356,"cells":5288},"dexfenfluramine",{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5293,"PHASE3":5295,"PHASE4":5297,"NA":5299},{"trials":5290,"activeCount":97},[],{"trials":5292,"activeCount":97},[],{"trials":5294,"activeCount":97},[],{"trials":5296,"activeCount":97},[],{"trials":5298,"activeCount":97},[],{"trials":5300,"activeCount":97},[5301],{"nctId":5302,"briefTitle":5303,"status":105,"phases":5304,"primaryCompletion":3856,"completion":3856,"start":5305,"enrollment":394,"conditions":5306,"interventions":5309},"NCT01296802","Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging",[90],"2006-04",[5307,5308],"Amphetamine-Related Disorders","Amphetamine Abuse",[5287],{"intervention":5311,"totalTrials":356,"cells":5312},"GHB 35 mg\u002Fkg p.o.",{"EARLY_PHASE1":5313,"PHASE1":5315,"PHASE2":5317,"PHASE3":5319,"PHASE4":5321,"NA":5323},{"trials":5314,"activeCount":97},[],{"trials":5316,"activeCount":97},[],{"trials":5318,"activeCount":97},[],{"trials":5320,"activeCount":97},[],{"trials":5322,"activeCount":97},[],{"trials":5324,"activeCount":97},[5325],{"nctId":5326,"briefTitle":5327,"status":105,"phases":5328,"primaryCompletion":5329,"completion":1168,"start":5330,"enrollment":3405,"conditions":5331,"interventions":5334},"NCT02342366","Characterization of the Prosocial and Prosexual Effects of GHB",[90],"2014-11","2012-02",[5047,5332,5333],"Bipolar Disorder","Autistic Disorder",[5311,5335],"GHB 20 mg\u002Fkg p.o.",{"intervention":5335,"totalTrials":356,"cells":5337},{"EARLY_PHASE1":5338,"PHASE1":5340,"PHASE2":5342,"PHASE3":5344,"PHASE4":5346,"NA":5348},{"trials":5339,"activeCount":97},[],{"trials":5341,"activeCount":97},[],{"trials":5343,"activeCount":97},[],{"trials":5345,"activeCount":97},[],{"trials":5347,"activeCount":97},[],{"trials":5349,"activeCount":97},[5350],{"nctId":5326,"briefTitle":5327,"status":105,"phases":5351,"primaryCompletion":5329,"completion":1168,"start":5330,"enrollment":3405,"conditions":5352,"interventions":5353},[90],[5047,5332,5333],[5311,5335],{"intervention":5355,"totalTrials":356,"cells":5356},"Pigmanorm Cream",{"EARLY_PHASE1":5357,"PHASE1":5359,"PHASE2":5361,"PHASE3":5363,"PHASE4":5365,"NA":5367},{"trials":5358,"activeCount":97},[],{"trials":5360,"activeCount":97},[],{"trials":5362,"activeCount":97},[],{"trials":5364,"activeCount":97},[],{"trials":5366,"activeCount":97},[],{"trials":5368,"activeCount":97},[5369],{"nctId":5370,"briefTitle":5371,"status":105,"phases":5372,"primaryCompletion":3404,"completion":3404,"start":756,"enrollment":1056,"conditions":5373,"interventions":5375},"NCT02153697","Comparative Study of the Therapy of Solar Lentigines With a Q-switched Rubin Laser Versus a Bleaching Cream",[90],[5374],"Solar Lentigines",[5355],{"intervention":5377,"totalTrials":356,"cells":5378},"Pycnogenol",{"EARLY_PHASE1":5379,"PHASE1":5381,"PHASE2":5383,"PHASE3":5385,"PHASE4":5387,"NA":5389},{"trials":5380,"activeCount":97},[],{"trials":5382,"activeCount":97},[],{"trials":5384,"activeCount":97},[],{"trials":5386,"activeCount":97},[],{"trials":5388,"activeCount":97},[],{"trials":5390,"activeCount":97},[5391],{"nctId":5392,"briefTitle":5393,"status":105,"phases":5394,"primaryCompletion":776,"completion":776,"start":4558,"enrollment":352,"conditions":5395,"interventions":5396},"NCT00641758","Pycnogenol and Endothelial Function in Coronary Artery Disease",[90],[890],[5377],{"intervention":5398,"totalTrials":356,"cells":5399},"L-lysine",{"EARLY_PHASE1":5400,"PHASE1":5402,"PHASE2":5404,"PHASE3":5406,"PHASE4":5408,"NA":5410},{"trials":5401,"activeCount":97},[],{"trials":5403,"activeCount":97},[],{"trials":5405,"activeCount":97},[],{"trials":5407,"activeCount":97},[],{"trials":5409,"activeCount":97},[],{"trials":5411,"activeCount":97},[5412],{"nctId":5413,"briefTitle":5414,"status":105,"phases":5415,"primaryCompletion":796,"completion":4334,"start":4103,"enrollment":4379,"conditions":5416,"interventions":5417},"NCT01579799","The Effect of L-lysine on Human Gastrointestinal Secretion: A Dose-finding Study Applying Magnetic Resonance Imaging (MRI)",[90],[15],[5398],{"intervention":5419,"totalTrials":356,"cells":5420},"Amisulpride",{"EARLY_PHASE1":5421,"PHASE1":5423,"PHASE2":5425,"PHASE3":5427,"PHASE4":5429,"NA":5431},{"trials":5422,"activeCount":97},[],{"trials":5424,"activeCount":97},[],{"trials":5426,"activeCount":97},[],{"trials":5428,"activeCount":97},[],{"trials":5430,"activeCount":97},[],{"trials":5432,"activeCount":97},[5433],{"nctId":5434,"briefTitle":5435,"status":105,"phases":5436,"primaryCompletion":3517,"completion":3517,"start":4125,"enrollment":5437,"conditions":5438,"interventions":5440},"NCT02557984","Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity",[90],121,[5439],"Addiction",[5419,5441],"Naltrexone",{"intervention":5441,"totalTrials":356,"cells":5443},{"EARLY_PHASE1":5444,"PHASE1":5446,"PHASE2":5448,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5445,"activeCount":97},[],{"trials":5447,"activeCount":97},[],{"trials":5449,"activeCount":97},[],{"trials":5451,"activeCount":97},[],{"trials":5453,"activeCount":97},[],{"trials":5455,"activeCount":97},[5456],{"nctId":5434,"briefTitle":5435,"status":105,"phases":5457,"primaryCompletion":3517,"completion":3517,"start":4125,"enrollment":5437,"conditions":5458,"interventions":5459},[90],[5439],[5419,5441],{"intervention":5461,"totalTrials":356,"cells":5462},"hypertension",{"EARLY_PHASE1":5463,"PHASE1":5465,"PHASE2":5467,"PHASE3":5469,"PHASE4":5471,"NA":5473},{"trials":5464,"activeCount":97},[],{"trials":5466,"activeCount":97},[],{"trials":5468,"activeCount":97},[],{"trials":5470,"activeCount":97},[],{"trials":5472,"activeCount":97},[],{"trials":5474,"activeCount":97},[5475],{"nctId":5476,"briefTitle":5477,"status":105,"phases":5478,"completion":1696,"start":776,"enrollment":1253,"conditions":5479,"interventions":5481},"NCT01252368","Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)",[],[5480,1437],"Healthy Participants",[5461],{"intervention":5483,"totalTrials":356,"cells":5484},"Tooth Mousse",{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5489,"PHASE3":5491,"PHASE4":5493,"NA":5495},{"trials":5486,"activeCount":97},[],{"trials":5488,"activeCount":97},[],{"trials":5490,"activeCount":97},[],{"trials":5492,"activeCount":97},[],{"trials":5494,"activeCount":97},[],{"trials":5496,"activeCount":97},[5497],{"nctId":5498,"briefTitle":5499,"status":105,"phases":5500,"primaryCompletion":2243,"completion":2073,"start":3996,"enrollment":1056,"conditions":5501,"interventions":5503},"NCT01566357","Impact of Milk on Erosion\u002FAbrasion of Enamel and Dentin - an in Situ Study",[90],[5502],"Erosion Protection",[5483,5504,5505],"MI Paste Plus","Elmex Erosion Protection",{"intervention":5504,"totalTrials":356,"cells":5507},{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5512,"PHASE3":5514,"PHASE4":5516,"NA":5518},{"trials":5509,"activeCount":97},[],{"trials":5511,"activeCount":97},[],{"trials":5513,"activeCount":97},[],{"trials":5515,"activeCount":97},[],{"trials":5517,"activeCount":97},[],{"trials":5519,"activeCount":97},[5520],{"nctId":5498,"briefTitle":5499,"status":105,"phases":5521,"primaryCompletion":2243,"completion":2073,"start":3996,"enrollment":1056,"conditions":5522,"interventions":5523},[90],[5502],[5483,5504,5505],{"intervention":5505,"totalTrials":356,"cells":5525},{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5530,"PHASE3":5532,"PHASE4":5534,"NA":5536},{"trials":5527,"activeCount":97},[],{"trials":5529,"activeCount":97},[],{"trials":5531,"activeCount":97},[],{"trials":5533,"activeCount":97},[],{"trials":5535,"activeCount":97},[],{"trials":5537,"activeCount":97},[5538],{"nctId":5498,"briefTitle":5499,"status":105,"phases":5539,"primaryCompletion":2243,"completion":2073,"start":3996,"enrollment":1056,"conditions":5540,"interventions":5541},[90],[5502],[5483,5504,5505],{"intervention":5543,"totalTrials":356,"cells":5544},"Allergovit",{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5549,"PHASE3":5551,"PHASE4":5553,"NA":5555},{"trials":5546,"activeCount":97},[],{"trials":5548,"activeCount":97},[],{"trials":5550,"activeCount":97},[],{"trials":5552,"activeCount":97},[],{"trials":5554,"activeCount":97},[],{"trials":5556,"activeCount":97},[5557],{"nctId":5558,"briefTitle":5559,"status":105,"phases":5560,"primaryCompletion":5561,"completion":4079,"start":5562,"enrollment":19,"conditions":5563,"interventions":5564},"NCT04104828","Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants",[],"2021-03-31","2019-11-05",[501],[5543,5565,5566],"Polvac","Pollinex Quattro",{"intervention":5565,"totalTrials":356,"cells":5568},{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5577,"NA":5579},{"trials":5570,"activeCount":97},[],{"trials":5572,"activeCount":97},[],{"trials":5574,"activeCount":97},[],{"trials":5576,"activeCount":97},[],{"trials":5578,"activeCount":97},[],{"trials":5580,"activeCount":97},[5581],{"nctId":5558,"briefTitle":5559,"status":105,"phases":5582,"primaryCompletion":5561,"completion":4079,"start":5562,"enrollment":19,"conditions":5583,"interventions":5584},[],[501],[5543,5565,5566],{"intervention":5566,"totalTrials":356,"cells":5586},{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5593,"PHASE4":5595,"NA":5597},{"trials":5588,"activeCount":97},[],{"trials":5590,"activeCount":97},[],{"trials":5592,"activeCount":97},[],{"trials":5594,"activeCount":97},[],{"trials":5596,"activeCount":97},[],{"trials":5598,"activeCount":97},[5599],{"nctId":5558,"briefTitle":5559,"status":105,"phases":5600,"primaryCompletion":5561,"completion":4079,"start":5562,"enrollment":19,"conditions":5601,"interventions":5602},[],[501],[5543,5565,5566],{"intervention":5604,"totalTrials":356,"cells":5605},"Hepatitis A vaccine and tetanus vaccine",{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5610,"PHASE3":5612,"PHASE4":5614,"NA":5616},{"trials":5607,"activeCount":97},[],{"trials":5609,"activeCount":97},[],{"trials":5611,"activeCount":97},[],{"trials":5613,"activeCount":97},[],{"trials":5615,"activeCount":97},[],{"trials":5617,"activeCount":97},[5618],{"nctId":5619,"briefTitle":5620,"status":105,"phases":5621,"primaryCompletion":1099,"completion":5622,"start":1206,"enrollment":5623,"conditions":5624,"interventions":5627},"NCT01947465","Immunogenicity and Safety of Vaccinations in Immunocompromised Persons",[],"2016-02",645,[2699,5625,5626],"Spondylarthritis","Vasculitis",[5604],{"intervention":5629,"totalTrials":356,"cells":5630},"therapy with disease-modifying anti rheumatic drugs",{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5635,"PHASE3":5637,"PHASE4":5639,"NA":5641},{"trials":5632,"activeCount":97},[],{"trials":5634,"activeCount":97},[],{"trials":5636,"activeCount":97},[],{"trials":5638,"activeCount":97},[],{"trials":5640,"activeCount":97},[],{"trials":5642,"activeCount":97},[5643],{"nctId":5644,"briefTitle":5645,"status":119,"phases":5646,"completion":797,"start":4288,"enrollment":1056,"conditions":5647,"interventions":5649},"NCT01292616","Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement",[],[5648],"Rheumatoid Arthritis",[5629],{"intervention":5651,"totalTrials":356,"cells":5652},"Baclofen",{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5654,"activeCount":97},[],{"trials":5656,"activeCount":97},[],{"trials":5658,"activeCount":97},[],{"trials":5660,"activeCount":97},[],{"trials":5662,"activeCount":97},[],{"trials":5664,"activeCount":97},[5665],{"nctId":5666,"briefTitle":5667,"status":105,"phases":5668,"primaryCompletion":1696,"completion":1696,"start":5669,"enrollment":19,"conditions":5670,"interventions":5672},"NCT01053585","Structure and Function of the Gastro-esophageal Junction",[90],"2007-02",[5671],"Gastroesophageal Reflux Disease",[5651],{"intervention":5674,"totalTrials":356,"cells":5675},"Yellow Fever Vaccination",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5682,"PHASE4":5684,"NA":5686},{"trials":5677,"activeCount":97},[],{"trials":5679,"activeCount":97},[],{"trials":5681,"activeCount":97},[],{"trials":5683,"activeCount":97},[],{"trials":5685,"activeCount":97},[],{"trials":5687,"activeCount":97},[5688],{"nctId":5689,"briefTitle":5690,"status":119,"phases":5691,"primaryCompletion":2721,"completion":1312,"start":1168,"enrollment":415,"conditions":5692,"interventions":5695},"NCT02383680","Yellow Fever Vaccination Under Low Dose Methotrexate Therapy",[],[5693,5694],"Rheumatic","Dermatologic Disorders",[5674],{"intervention":5697,"totalTrials":356,"cells":5698},"Fentanyl",{"EARLY_PHASE1":5699,"PHASE1":5701,"PHASE2":5703,"PHASE3":5705,"PHASE4":5707,"NA":5709},{"trials":5700,"activeCount":97},[],{"trials":5702,"activeCount":97},[],{"trials":5704,"activeCount":97},[],{"trials":5706,"activeCount":97},[],{"trials":5708,"activeCount":97},[],{"trials":5710,"activeCount":97},[5711],{"nctId":5712,"briefTitle":5713,"status":105,"phases":5714,"primaryCompletion":2925,"completion":2925,"start":5715,"enrollment":1315,"conditions":5716,"interventions":5718},"NCT05740657","Observational Study on the Incorporation of Opioids and Their Metabolites Into Hair of Pediatric Patients",[],"2022-12-06",[5717],"Opioid Use, Unspecified",[5697],{"intervention":5720,"totalTrials":356,"cells":5721},"sevelamer, sodium bicarbonate, sodium chloride",{"EARLY_PHASE1":5722,"PHASE1":5724,"PHASE2":5726,"PHASE3":5728,"PHASE4":5730,"NA":5732},{"trials":5723,"activeCount":97},[],{"trials":5725,"activeCount":97},[],{"trials":5727,"activeCount":97},[],{"trials":5729,"activeCount":97},[],{"trials":5731,"activeCount":97},[],{"trials":5733,"activeCount":97},[5734],{"nctId":5735,"briefTitle":5736,"status":105,"phases":5737,"primaryCompletion":1312,"completion":1312,"start":2721,"enrollment":36,"conditions":5738,"interventions":5739},"NCT02822131","Phosphate in Blood Pressure Regulation",[90],[1437],[5720],{"intervention":5741,"totalTrials":356,"cells":5742},"Tocilizumab",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5747,"PHASE3":5749,"PHASE4":5751,"NA":5753},{"trials":5744,"activeCount":97},[],{"trials":5746,"activeCount":97},[],{"trials":5748,"activeCount":97},[],{"trials":5750,"activeCount":97},[],{"trials":5752,"activeCount":97},[],{"trials":5754,"activeCount":97},[5755],{"nctId":5756,"briefTitle":5757,"status":105,"phases":5758,"primaryCompletion":2962,"completion":1312,"start":1055,"enrollment":473,"conditions":5759,"interventions":5762},"NCT01073826","Role of Interleukin-6 in Exercise",[90],[5760,5761],"Diabetes Mellitus, Type 2","Obesity",[5741,5763],"Sitagliptin",{"intervention":5763,"totalTrials":356,"cells":5765},{"EARLY_PHASE1":5766,"PHASE1":5768,"PHASE2":5770,"PHASE3":5772,"PHASE4":5774,"NA":5776},{"trials":5767,"activeCount":97},[],{"trials":5769,"activeCount":97},[],{"trials":5771,"activeCount":97},[],{"trials":5773,"activeCount":97},[],{"trials":5775,"activeCount":97},[],{"trials":5777,"activeCount":97},[5778],{"nctId":5756,"briefTitle":5757,"status":105,"phases":5779,"primaryCompletion":2962,"completion":1312,"start":1055,"enrollment":473,"conditions":5780,"interventions":5781},[90],[5760,5761],[5741,5763],{"intervention":5783,"totalTrials":356,"cells":5784},"Vi-De 3",{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5789,"PHASE3":5791,"PHASE4":5793,"NA":5795},{"trials":5786,"activeCount":97},[],{"trials":5788,"activeCount":97},[],{"trials":5790,"activeCount":97},[],{"trials":5792,"activeCount":97},[],{"trials":5794,"activeCount":97},[],{"trials":5796,"activeCount":97},[5797],{"nctId":5798,"briefTitle":5799,"status":105,"phases":5800,"primaryCompletion":5801,"completion":5801,"start":3404,"enrollment":3405,"conditions":5802,"interventions":5805},"NCT02279316","Move for Your Mind - Pilot Trial",[90],"2016-09",[2770,5803,5804],"Mild Dementia","Fall Prevention",[5783],{"intervention":5807,"totalTrials":356,"cells":5808},"Tamsulosin",{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5817,"NA":5819},{"trials":5810,"activeCount":97},[],{"trials":5812,"activeCount":97},[],{"trials":5814,"activeCount":97},[],{"trials":5816,"activeCount":97},[],{"trials":5818,"activeCount":97},[],{"trials":5820,"activeCount":97},[5821],{"nctId":5822,"briefTitle":5823,"status":105,"phases":5824,"primaryCompletion":4946,"completion":4946,"start":5825,"enrollment":124,"conditions":5826,"interventions":5828},"NCT00831701","Medical Expulsive Therapy of Single Distal Ureteral Stones",[90],"2006-09",[5827],"Ureteral Calculi",[5807],{"intervention":5830,"totalTrials":356,"cells":5831},"Syntocinon®",{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5836,"PHASE3":5838,"PHASE4":5840,"NA":5842},{"trials":5833,"activeCount":97},[],{"trials":5835,"activeCount":97},[],{"trials":5837,"activeCount":97},[],{"trials":5839,"activeCount":97},[],{"trials":5841,"activeCount":97},[],{"trials":5843,"activeCount":97},[5844],{"nctId":5845,"briefTitle":5846,"status":119,"phases":5847,"primaryCompletion":4334,"completion":107,"start":1870,"enrollment":394,"conditions":5848,"interventions":5850},"NCT01066299","Influence of Oxytocin on the Startle Reflex and on Its Modulation",[90],[5849],"Psychiatric Disorders",[5830,5851],"inactive nasal spray",{"intervention":5851,"totalTrials":356,"cells":5853},{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5860,"PHASE4":5862,"NA":5864},{"trials":5855,"activeCount":97},[],{"trials":5857,"activeCount":97},[],{"trials":5859,"activeCount":97},[],{"trials":5861,"activeCount":97},[],{"trials":5863,"activeCount":97},[],{"trials":5865,"activeCount":97},[5866],{"nctId":5845,"briefTitle":5846,"status":119,"phases":5867,"primaryCompletion":4334,"completion":107,"start":1870,"enrollment":394,"conditions":5868,"interventions":5869},[90],[5849],[5830,5851],{"intervention":5871,"totalTrials":356,"cells":5872},"CAir",{"EARLY_PHASE1":5873,"PHASE1":5875,"PHASE2":5877,"PHASE3":5879,"PHASE4":5881,"NA":5883},{"trials":5874,"activeCount":97},[],{"trials":5876,"activeCount":97},[],{"trials":5878,"activeCount":97},[],{"trials":5880,"activeCount":97},[],{"trials":5882,"activeCount":97},[],{"trials":5884,"activeCount":97},[5885],{"nctId":5886,"briefTitle":5887,"status":105,"phases":5888,"primaryCompletion":5889,"completion":5889,"start":5890,"enrollment":4243,"conditions":5891,"interventions":5894},"NCT04373070","Quality-of-Life Management for COPD Patients",[90],"2022-05-30","2021-02-03",[5892,5893],"Copd","Chronic Respiratory Disease",[5871],{"intervention":5896,"totalTrials":356,"cells":5897},"Sevoflurane\u002Fpropofol",{"EARLY_PHASE1":5898,"PHASE1":5900,"PHASE2":5902,"PHASE3":5904,"PHASE4":5906,"NA":5908},{"trials":5899,"activeCount":97},[],{"trials":5901,"activeCount":97},[],{"trials":5903,"activeCount":97},[],{"trials":5905,"activeCount":97},[],{"trials":5907,"activeCount":97},[],{"trials":5909,"activeCount":97},[5910],{"nctId":5911,"briefTitle":5912,"status":105,"phases":5913,"primaryCompletion":441,"completion":441,"start":1848,"enrollment":5914,"conditions":5915,"interventions":5917},"NCT00515905","One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators",[90],76,[5916],"Thoracic Surgery With One-lung Ventilation",[5896]]